MINI REVIEW article

Front. Immunol., 16 September 2021

Sec. Multiple Sclerosis and Neuroimmunology

Volume 12 - 2021 | https://doi.org/10.3389/fimmu.2021.739130

PET Imaging of Neuroinflammation in Alzheimer’s Disease

  • 1. Department of Nephrology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China

  • 2. Department of Radiopharmacy and Molecular Imaging, School of Pharmacy, Fudan University, Shanghai, China

  • 3. Positron Emission Tomography (PET) Center, Huashan Hospital, Fudan University, Shanghai, China

  • 4. Inner Mongolia Baicaotang Qin Chinese Mongolia Hospital, Hohhot, China

  • 5. School of Information Science and Technology, Shanghaitech University, Shanghai, China

  • 6. Institute for Regenerative Medicine, University of Zurich, Zurich, Switzerland

  • 7. Institute for Biomedical Engineering, University of Zurich & Eidgenössische Technische Hochschule Zürich (ETH Zurich), Zurich, Switzerland

Article metrics

View details

152

Citations

28k

Views

17,6k

Downloads

Abstract

Neuroinflammation play an important role in Alzheimer’s disease pathogenesis. Advances in molecular imaging using positron emission tomography have provided insights into the time course of neuroinflammation and its relation with Alzheimer’s disease central pathologies in patients and in animal disease models. Recent single-cell sequencing and transcriptomics indicate dynamic disease-associated microglia and astrocyte profiles in Alzheimer’s disease. Mitochondrial 18-kDa translocator protein is the most widely investigated target for neuroinflammation imaging. New generation of translocator protein tracers with improved performance have been developed and evaluated along with tau and amyloid imaging for assessing the disease progression in Alzheimer’s disease continuum. Given that translocator protein is not exclusively expressed in glia, alternative targets are under rapid development, such as monoamine oxidase B, matrix metalloproteinases, colony-stimulating factor 1 receptor, imidazoline-2 binding sites, cyclooxygenase, cannabinoid-2 receptor, purinergic P2X7 receptor, P2Y12 receptor, the fractalkine receptor, triggering receptor expressed on myeloid cells 2, and receptor for advanced glycation end products. Promising targets should demonstrate a higher specificity for cellular locations with exclusive expression in microglia or astrocyte and activation status (pro- or anti-inflammatory) with highly specific ligand to enable in vivo brain imaging. In this review, we summarised recent advances in the development of neuroinflammation imaging tracers and provided an outlook for promising targets in the future.

Introduction

Neurodegenerative diseases, including Alzheimer’s disease (AD), frontotemporal dementia, Parkinson’s disease (PD), and Lewy body dementia, represent a tremendous unmet clinical need. The major neuropathological features of AD are the deposition of amyloid-beta (Aβ) plaques, neurofibrillary tangles formed by misfolded hyperphosphorylated tau, neuronal loss, and neuroinflammation characterised by glial activation (1, 2). Neuroinflammation plays an important role in AD; however, its dynamics and impacts (protective or detrimental) have still not been fully elucidated (3, 4). Microglia, as the resident macrophage cells in the brain, have emerged as central players in the AD pathogenesis (1, 2, 5). Microglial activation was previous classified into proinflammatory (M1) or anti-inflammatory (M2) types (2). Recent single-cell sequencing and transcriptomics studies reported gene coexpression network diversity of microglia in AD and disease-associated-microglia (DAM) of transcriptionally distinct and neurodegeneration-specific profiles (6–12). Aβ-laden microglia has a unique gene-expression signature including triggering receptor expressed on myeloid cells 2 (TREM2), apolipoprotein E (ApoE), and other AD-associated genes (13, 14). Microglia phagocytosis driven by Tyro3, Axl, and Mer (TAM) receptor has been shown to promote the development of dense-core plaque and the engulfing of Aβ plaques (15). Astrocytes are categorised into A1 and A2 subtypes based on their phenotype and genetic expression profiles (16–19). A1 astrocyte secretes and produces a large number of inflammatory factors and neurotoxins, whereas A2 astrocyte produces neurotrophic substances and supports neuronal growth. Reactive astrocytes precipitate both Aβ and tau (20–22) and are closely linked with microgliosis (16). Cerebrospinal fluid (CSF) and plasma biomarkers for neurodegeneration and inflammatory markers [e.g., tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), IL-10] were elevated in patients with AD and mild cognitive impairment (MCI) compared to healthy controls (6, 7, 13, 14), associated with an increasing age (23, 24) and cerebral amyloid pathology (25). Recent advances in molecular imaging have provided insights into the time course of AD pathology, including Aβ, tau, synaptic deficits, and neuroinflammation, in patients and in animal disease models (1, 26–35). In vivo imaging of neuroinflammation, however, is challenging, and the spatial–temporal pattern in the development of AD has still not been fully elucidated (23). One reason is that the astrocytes and microglia are highly dynamic and heterogeneous in their subtypes, locations, and activation status (1).

Neuroinflammation Positron Emission Tomography Imaging

Mitochondrial 18 kDa translocator protein (TSPO) is the most widely investigated neuroinflammation target for PET imaging (36). Other alternative targets are under rapid development (Table 1), such as monoamine oxidase-B (MAO-B), matrix metalloproteinases (144–147, 185, 186), colony-stimulating factor 1 receptor (CSF1R), imidazoline-2 binding sites (I2BS), cyclooxygenases, the phospholipase A2/arachidonic acid pathway, sphingosine-1-phosphate receptor-1, reactive oxygen species, cannabinoid-2 receptor, purinergic P2X7 receptor and P2Y12 receptor, the fractalkine receptor (CX3CR1) (187), TREM2 (140), and receptor for advanced glycation end products (36, 188) (Table 1).

Table 1

TargetTracerHumanAnimal model
TSPO(R)-[11C] PK11195MCI, AD, HC (37–43)3×Tg, APP/PS1 mice, rTg4510 mice (26, 44)
[18F]DPA-714AD, MS, ALS, HC (45, 46)APP/PS1 mice, TgF344 rats (47–51)
[11C]DPA-713AD, HC (52)Murine stroke models (53), aged Monkeys (54)
[18F]F-DPAAPP/PS1 mice (55)
[18F]FEBMPPS19, rTg4510 mice (56–58)
[11C]DAA1106, [18F]FEDAA1106AD, HCAPP23, APP/PS1, PS19 mice, TgF334 rats (50, 59, 60)
[18F]FEMPAAD, HC (61, 62)
[11C]AC-5216HC (63)APP23, AppNL-G-F/NL-G-F-knock-in, APPE693, rTg4510, PS19 mice (26, 57, 60, 64, 65)
[18F]FEPPAMCI, AD, HC (66, 67)TgAPP21 rats (68)
[11C]PBR06MCI, AD, HC (69–71)APPL/S mice (57, 72, 73)
[11C]PBR28AD, SD, MCI, FTD, DLB, ALS, HC (40, 69, 74–82)5×FAD, PS19 mice (57, 73)
[18F]PBR111APP/PS1 mice (83, 84)
[125I]CLINDEAD, HC (85)LPS injected, 3×Tg mice, TgF344 rats (85–87)
[18F]GE-180AD, MS, FTD, HC (88–91)APP/PS1, PS2APP, APP23, APP-SL70, APPswe, APPNL-G-F, APPL/S, Trem2 p.T66M knock-in, PS19 mice, TgF344 rats (47, 50, 53, 90, 92–102)
(S)-[18F]GE-387, (R, S)-[18F]GE-387HC (103)LPS injected rats, non-human primates (103, 104)
[11C]ER176HC (75, 105, 106)
[11C]CB184, [11C]CB190Mice, 6-OHDA injected rats (107)
[11C]N′-MPBStroke rat model (108)
[18F]LW223HC (109)Rats (109)
P2X7R[11C]GSK1482160HC (110)LPS-injected mice, EAE rats, non-human primates (110, 111)
[18F]JNJ-64413739HC (112), ALS (113)LPS injected mice (112, 114)
[11C]JNJ-54173717ALS (113)rAAV3flag-hP2X7R, α-synuclein, 6-OHDA injected rats, non-human primates (115, 116).
[11C]SMW139MS (117)EAE, rAAV3flag-hP2X7R rats (118, 119)
[11C]JNJ-47965567 (A-740003)MS (120)Rats (121)
P2Y12R[11C]P2Y12R-antMS (120)EAE rats (120)
[11C]5Stroke (122)Murine stroke model (122)
[11C]AZD1283rTg4510, PS19, APP23, and APPNL-F/NL-F mice, ex vivo (123)
CSF1R[11C]CPPCAD, HC (124)LPS injected, EAE, APPsi, APPNL-G-F/NL-G-Fknock-in mice (64, 124)
[11C]GW2580LPS injected, APPNL-G-F/NL-G-Fknock-in mice, non-human primates (64)
COX-1[11C]-KTP-MeAD, HC (125, 126)APPswe mice (125–127)
[11C]PS13, [18F]PS2LPS treated rhesus macaques (128)
COX-2[11C]MC1LPS treated rhesus macaques (129)
[18F]FMTPLPS injected mice (130)
[18F]TMINon-human primates (131)
iNOS[18F]FBATLPS injected mice (132)
ROS[18F]ROStrace [18F]ox-ROStrace,LPS-treated mice (133)
[18F]dihydromethidine,LPS-treated mice (134)
[11C]Ascorbic. [11C]dehydroascorbic acidRats (135)
[62Cu]ATSMPD, ALS, MELAS (136, 137)Brain tumor mice (138, 139)
TREM-2[124I]mAb1729,mAb1729-scFv8D3CLAPPArcSwe, APPswe mice (140)
TREM-1 [64Cu]TREM1-mAbMurine stroke, MS, GBM models (141–143)
Murine glioma and metastatic breast cancer model (144–146)
MMP[18F]BR-351, [18F]BR-420Murine stroke models (147, 148)
CB2R[11C]A-836339, [18F]2fHC (149)J20APPswe/ind, APP/PS1 mice (150)
[18F]RS-126, [18F]RoSMA-18-d6LPS injected, Huntington, stroke mice (151, 152)
[18F]JHU94620LPS injected mice (153)
[11C]NE40AD, HC (154)SAMP10 mice (155)
MAO-B[11C]DEDMCI, AD, HC (156–162)APPArcSwe, APPswe mice (163, 164)
[18F]fluorodeprenyl-D2Non-human primates (165)
[18F]SMBT-1AD, HC (166, 167)
[11C]SL25.1188HC, MDD (168, 169)LPS-injected rats (170)
astrocyte[11C]acetateMCI, MS, HC (171, 172)
I2BS[11C]BU99008AD, PD, HC (173–178)Zucker rats, Non-human primates (179–181)
[¹⁸F]FEBU (BU99018)Mice and rats (182)
[¹¹C]FTIMDNon-human primates (183)
OATP1C1[18F]2B-SRF1013×Tg mice (184)

Summary of imaging probes for gliosis.

ALS, amyotrophic lateral sclerosis; COX-1/2, cyclooxygenase 1/2; CSF1R, colony stimulating factor 1 receptor; DED, deuterium-L-deprenyl; FTD, Frontotemporal dementia; GBM, glioblastoma; HC, healthy control; iNOS, inducible nitric oxide synthase; I2BS, I2-imidazoline binding sites; LPS, lipopolysaccharides; MCI, mild cognitive impairment; MDD, major depressive disorder; MELAS, mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes; MMP, matrix metalloproteinases; MS, multiple sclerosis; OATP1C1, organic anion-transporting polypeptide 1C1; ROS, reactive oxygen species; PD, Parkinson’s disease; SD, semantic dementia; TREM-1, 2, triggering receptor expressed on myeloid cells 1, 2; TSPO, translocator protein; 6-OHD, 6-hydroxydopamine.

TSPO Imaging

TSPO is expressed mainly in the outer mitochondrial membrane of steroid-synthesizing cells in the central nervous system (microglia, astrocytes, endothelial cell, etc.) (Figures 1A, B) and in the peripheral (191). TSPO is involved in many physiological processes including transporting cholesterol into mitochondria, steroid hormone synthesis, and bioenergetics (191, 192). Upregulation of TSPO was found in patients with AD and in animal models of AD (92, 193).

Figure 1

The First Generation TSPO Tracers

The first-generation tracers exemplified with [11C]PK-11195 have been widely used in preclinical and clinical studies. However, [11C]PK-11195 suffers from several major limitations such as low permeability of the blood–brain barrier and high non-specific plasma binding, leading to a low signal-to-noise ratio in the final reconstructed PET images (194). Careful analysis of plasma metabolites is required to determine the accurate arterial input function for quantitative PET measurement (195). Increased [11C]PK11195 is reported to be associated with Aβ accumulation in patients with MCI and AD compared to healthy controls, correlating with the deficits in functional network connectivity, grey matters atrophy, and cognitive decline (37–39, 196). Using [11C]PK11195, recent studies have showed a biphasic trajectory of inflammation with an early microglial activation with increasing Aβ load and a later decline when Aβ load reaching plateau (AD) levels (40). Ismail et al. demonstrated a parallel increase in microglial activation and tau accumulation assessed by [11C]PK11195 and [18F]flortaucipir, respectively, in [11C]PIB Aβ-positive MCI patients (41). Su et al. further showed that grey matter atrophy mediated the effects of tau accumulation and neuroinflammation detected by PET tracers [18F]flortaucipir and [11C]PK11195, respectively on cognitive impairments in AD (42).

The Second Generation TSPO Tracers

A few second generation tracers including [11C]DAA1106, [1(F]FEDAA1106, [125I]CLINDE [11C]PBR06, [11C]PBR28, [18F]PBR111, [18F]DPA-713, [18F]DPA-714, [18F]F-DPA, [11C]AC-5216, [18F]FEMPA, and [18F]FEPPA have been developed to overcome the limitations of [11C]PK11195 (45, 46, 52, 61–63, 66, 69–71, 83, 84, 197) (Table 1). However, the binding affinities of second generation TSPO tracers in human brain differ based on the rs6971 polymorphisms, which introduces higher variability between subjects (45, 46, 52, 61–63, 66, 69–71, 197). In addition, the [11C]PBR28 binding appears to be affected by chromosome 1 variant rs2997325 on microglial activation (198). Several longitudinal studies using [18F]DPA-714, [11C]DAA1106, and [11C]PBR28 have reported decreased glucose metabolism and increased neuroinflammation in amyloidosis, four-repeat tauopathy animal models (47–50, 55) (Table 1). Ishikawa et al. has indicated an association between tau assessed by [11C]PBB3, neuronal damage measured by structural MRI, and neuroinflammation detected by using [11C]AC-5216 in rTg4510 mice (56–58). Chaney et al. showed an increased [18F]DPA-714 binding and myo-inositol levels using 1H magnetic resonance spectroscopy in APP/PS1 mice (48). Zou et al. showed that microglial activation assessed by [11C]PBR28 is independently associated with amyloid load and memory impairment, but not with tau burden assessed by [18F]florbetaben and [18F]MK-6240, respectively, in patients with AD (74). Whereas Dani et al. showed that [11C]PBR28-measured microglial activation correlates with both tau and Aβ deposition assessed by [18F]flortaucipir and [18F]flutemetamol in patients with AD (69) (Figures 2D, E). Studies by Femminell et al. demonstrated an increased regional [11C]PBR28 binding in patient with MCI, which associated with higher grey matter and hippocampal volume (199). This suggests a potential protective effect of microglia activation in the early stages (199). Hamelin et al. showed a diverging pattern of progression in AD based on [18F]DPA-714 baseline binding, with a higher baseline associates with less subsequent microglial activation and better cognitive performance in 2-years follow-up (45).

Figure 2

The Third Generation TSPO Tracers

Several third generations of TSPO tracers [18F]GE-180, (R,S)-[18F]GE-387, [11C]ER176, [11C]CB184, [11C]CB190, [11C]N′-MPB, and [18F]LW223 have been developed (75, 103, 105–109). [18F]GE-180 (flutriciclamide), (S)-[18F]GE-387, and [11C]ER176 resolve the problem of ligand-dependent attenuation of affinity (90, 97, 197) in in vitro binding assay where these tracers are insensitive to TSPO rs6971 polymorphisms (104). The rs6971 polymorphisms, however, affects in vivo [18F]GE-180 quantification, revealing lower binding in patients of low-affinity binders compared to the mixed- and high-affinity binders (88). Several studies have compared the binding properties and performance of second and third generations of TSPO tracers. James et al. found that the detection of microglial activation by using [18F]GE180 was more sensitive than that by using [18F]PBR06 (94). However, Chaney et al. indicated that [11C]DPA-713 PET reflects microglial activation with higher accuracy and sensitivity compared to [18F]GE-180 in a mouse model of stroke (53). Head-to-head comparative PET study by Zanotti-Fregonara et al. showed a more favourable brain entrance property of [11C]PBR28 compared to [18F]GE-180 in human (76). [11C]ER176 has demonstrated a higher binding potential and smaller variability compared to [11C]PK11195, [11C]PBR28, and [11C]DPA-713 (75, 105, 106). Clinical trial of PET using [11C]ER176 for accessing microglia activation in patients with MCI and AD is still ongoing (NCT03744312). Microglial activation assessed by using [18F]GE-180 in different amyloidosis, tauopathy rodent models have been reported (47, 50, 53, 89, 90, 92–102) (Table 1). López-Picón et al. showed that [18F]GE-180 signal reached plateaus at an early stage, while the Aβ load detected by [11C]PIB was still increasing in APP23 mice (90). A recent study by Sacher et al. showed an asymmetric pattern (hemispheric predominance) of Aβ load ([18F]florbetaben) accompanied by microglial activation ([18F]GE-180) in AppNL-G-F knock-in mice (96). Increased levels of [18F]GE-180 uptake indicative of microglial activation have been reported in patients with AD, semantic dementia, MCI, and four-repeat tauopathy compared to non-demented controls (88–91). Ramakrishnan reported that [18F]GE-387 visualised increased uptake in rat of acute inflammation induced by lipopolysaccharides (LPS) injection and demonstrated sufficient brain uptake in non-human primate (104).

The cellular location of the signal is another major concern for TSPO ligands. Two different binding sites on glial and vascular TSPO were reported for several TSPO ligands, e.g., [11C]PK11195 (57). Ji et al. reported that polymorphism-insensitive ligand [18F]FEBMP (200) yielded a higher contrast to neuroinflammation than [11C]PK11195 in PS19 tauopathy mouse model due to its higher glial-TSPO selectivity (Figures 1F, G) (57, 58). Further studies evaluating the TSPO selectivity and insensitivity to TSPO polymorphism of the second and third generations TSPO tracers including [18F]GE-180, (S)-[18F]GE-387, and [11C]ER176 are highly desired.

Emerging Targets

Given that TSPO is not exclusively expressed in glia, it is thus imperative to search for new imaging biomarkers that can detect neuroinflammation with higher sensitivity and specificity. Promising targets should have almost exclusive expression in microglia or astrocyte and highly specific ligands to enable in vivo imaging evaluations (32, 170, 201, 202).

Colony-Stimulating Factor 1 Receptor

CSF1R is expressed mainly on microglia and on infiltrating macrophages/monocytes and dendritic cells in the brain (Figures 1A, B). CSF1R is important for microglia growth, proliferation, and survival. Two endogenous ligands, the growth factors colony stimulating factor-1 and interleukin-34 (203), have been reported for CSF1R. Upregulation in CSF1R have been reported in response to injury and AD-related neuropathology (204, 205). Horti et al. developed a new CSF1R tracer [11C]CPPC and captured increased microglial levels of CSF1R in animal models of acute inflammation induced by LPS injection, encephalomyelitis model of multiple sclerosis, and APPsi with cerebral Aβ pathology (124). A recent study from Zhou et al. compared new CSF1R tracers [11C]GW2580 with [11C]CPPC in detecting both acute inflammation induced by LPS injection and chronic inflammation in APPNL-G-F/NL-G-F knock-in mice and showed that [11C]GW2580 captured changes in CSF1R with higher sensitivity, associated with increased TSPO pattern in the brain (64) (Figures 1C–E).

Cyclooxygenase-1 and Cyclooxygenase-2

Cyclooxygenase (COX) is an enzyme involved in the production of prostaglandin H2, which is the substrate for molecules including prostaglandins, prostacyclin, and thromboxanes (206). The two isoforms COX-1 and COX-2 are considered to be involved in the neuroinflammation in neurodegenerative diseases including AD. Immunochemical evidence showed that COX-1 and COX-2 are expressed in microglia and neuron in the central nervous system (207). Several tracers for COX-1 and COX-2 have been developed including [18F]TMI (131, 208), [18F]triacoxib (209), [11C]rofecoxib (210), [11C]KTP-Me (125, 127, 211), [11C]PS13, and [11C]MC1 (128, 129) (Table 1). Ohnishi et al. and Shukuri et al. reported that [11C]KTP-Me harbours an improved brain–barrier entrance and is highly selective for COX-1 (125, 127, 211). PET study with [11C]KTP-Me showed an increased brain uptake in AD patients compared to healthy controls and in APPswe (Tg2576) mice compared to wild-type mice (125–127): [11C]KTP-Me accumulation was detected in the frontal cortex and hippocampus, in activated microglia surrounding Aβ plaques. Shrestha et al. reported PET imaging of COX-2 ([11C]MC1) and COX-1 ([11C]PS13) in monkey brain after LPS-induced neuroinflammation and in human peripheral tissue with inflammation and showed specific detection patterns (128, 129).

Cannabinoid Receptor Type 2

Cannabinoid receptor type 2 (CB2R) are mainly expressed by immune cells including monocytes, macrophages, and microglia in the brain (151, 152) and have low expression levels under physiological conditions (2, 4, 31). Several classes of tracers for CB2R have been developed including [11C] methoxy-Sch225336 (212), [11C]NE40 (154), [11C]A-836339, [18F]2f (149, 150), [18F]JHU94620 (153), [18F]RS-126, and [18F]RoSMA-18-d6 (151, 152) (Table 1). Upregulation of brain CB2R expression has been demonstrated in acute inflammation such as LPS-injected model and murine stroke model (151–153) in chronic inflammation senescence-accelerated models (155) and in amyloidosis mouse model associated with Aβ deposits (150). Ahmad et al. reported lower CB2R availability in Aβ-positive AD patients compared to healthy controls assessed by PET using [11C]NE40 and [11C]PIB, respectively. However, no relationship between [11C]NE40 and cerebral Aβ load was observed (154).

Purinergic P2X7 Receptor and P2Y12 Receptor

The expression of purinergic P2X7 receptor is found upregulated specifically in M1 microglia. P2X7 receptor mediates NLRP3 inflammasome activation, cytokine and chemokine release, T lymphocyte survival and differentiation, transcription factor activation, and cell death (213). Microglia monitors and protects neuronal function through purinergic P2Y12 receptor-dependent junctions (214) linked with neuronal mitochondrial activity. Brain injury-induced changes at somatic junctions triggered P2Y12-receptor-dependent microglial neuroprotective effect, regulating neuronal calcium load and functional connectivity (215, 216). Immunohistochemical staining indicated that the levels of P2Y12 receptor were decreased in the brains derived from patients with multiple sclerosis and AD cases (217). Several P2X7 receptor tracers including [11C]GSK1482160 (110, 111), [11C]JNJ-47965567 (A-740003) (120), [18F]JNJ-64413739 (112, 114), [11C]JNJ-54173717 (113), [11C]SMW139 (118), and [18F]PTTP (218). Janssen et al. showed that [11C]SMW139 can detect with high affinity and specificity to the P2X7 receptor by using rAAV3flag-hP2X7R rat model overexpressing human P2X7 receptor (119). Moreover, [11C]SMW139 showed higher binding on postmortem brain of AD patients compared to controls by using in vitro autoradiography studies, corroborating with immunohistochemical staining results (119). One clinical trial is ongoing using [11C]SMW139 for imaging neuroinflammation in Parkinson’s disease [(PRI-PD) 2018-000405-23].

Several P2Y12 receptor probes such as [11C]AZD1283, [11C]P2Y12R-ant, and [11C]5 have been developed and evaluated in vivo in animal models (120, 122, 123). Maeda et al. showed a distinct response of P2Y12 receptor to tau and amyloid deposits using P2Y12 receptor tracer [11C]AZD1283. The levels of P2Y12 receptor decline in tau-laden region with increased total level of microglia in rTg4510 and PS19 tau mice and increase in APP23 and APPNL-F/NL-F mice (123). However PET imaging using [11C]AZD1283 showed no uptake signal in the wild-type mouse brain. Two other tracers [11C]P2Y12R-ant and [11C]5 have showed sufficient brain uptake and promising results in experimental autoimmune encephalomyelitis model of multiple sclerosis (120) and stroke model for detecting anti-inflammatory microglia (122).

Astroglia Imaging

MAO-B

Irreversible MAO-B inhibitors [11C]deuterium-L-deprenyl (DED) have been used in PET imaging studies and demonstrated early astrocytosis in sporadic and autosomal dominant AD patients (61, 156–161, 163) and in amyloidosis mouse models (163, 164). [18F]fluorodeprenyl-D2 showed favorable kinetic properties with relatively fast washout from non-human primate brain and improved sensitivity for MAO-B imaging (165). However, the technical challenges of irreversible inhibitors such as deprenyl hinder the accurate image analysis. Several reversible-binding inhibitors have been developed in recent years such as [11C]Cou (170, 219), [11C]SL25.1188 (168), and [11C]SMBT-1 (166). Harada et al. showed a specific increased regional retention of [11C]SMBT-1 in the cortical and hippocampal regions in patients with AD compared to healthy controls (166).

I2BS

I2BS that locates on both monoamine oxidases A (MAO-A) and B (MAO-B) is another emerging target for astrocytosis imaging (173–175, 220). [¹¹C]FTIMD shows the specific-binging to I₂BS as shown by PET and autoradiography in the monkey brain (183). Wilson et al. demonstrated reactive astroglia detected by using [11C]BU99008 PET early in Parkinson’s disease in response to α-synuclein accumulation (174). Recent postmortem binding and autoradiography study by Kumar et al. showed increased level of [3H]BU99008 binding in postmortem brain tissue from patients with AD compared to healthy controls (173, 221). Calsolaro et al. recently demonstrated increased cortical astrocytosis assessed by [11C]BU99008 with high cerebral Aβ load assessed by [18F]florbetaben in patients with MCI and AD (176) (Figures 2A–C). Livingston et al. demonstrated that increased astrocytosis assessed by [11C]BU99008 in regions of earlier stages with low Aβ loads assessed by [18F]florbetaben and reduced astrocytosis in regions of advanced stage with greater Aβ load and atrophy (177). In vitro autoradiography and immune-histochemical staining showed the specificity of [3H]BU99008 and the colocalization of with glial fibrillary acidic protein staining of astroctyes in brain tissues from patients with AD.

Discussion

Non-invasive detection of central pathologies is indispensable for understanding the mechanism underlying AD continuum and for facilitating early and differential diagnosis (28, 222–225). TSPO-PET is still the most powerful imaging tool for AD-associated neuroinflammation but is currently facing two challenges. First, a human TSPO polymorphism TSPO rs6971 commonly affects the binding affinities of the second generation tracers to a different extent. Classification with polymorphism enables to correct the variability and bias from different binding affinities, but it raises the threshold for sample size of human subjects. Third-generation tracers have been developed for circumventing this limitation. In vitro testing in post-mortem human brain tissues have demonstrated the insensitivity of [11C]GE-180, [11C]GE-387, and [11C]ER176 to TSPO polymorphism (75, 106, 197). However, recent clinical study with [11C]ER176 (105) and [11C]GE-180 (88) demonstrated a significant decrease in ligand retention in low-affinity binders, suggesting the necessity of further in vivo examination. Second, the heterogenous cellular sources of TSPO PET tracers have been demonstrated in astrocytes, endothelial cells, and vascular smooth muscle cells, in addition to microglia in both patients with AD and animal models (61, 85, 86, 193, 226–229) (Figures 1A, B). Although conventional opinions consider microglia as major cellular source of TSPO in the central nervous system, latest study finds vascular TSPO provides major binding sites for TSPO ligands including most widely used [11C]PK11195 and [11C]PBR28 in normal mouse brains (57). These findings suggest the possibility that changes in TSPO PET signal may be partly due to changes in the levels of vascular TSPO and not purely of glial TSPO. [18F]FEBMP and [11C]AC-5216 showed relatively selectivity for glial-TSPO compared to other ligands such as [11C]PK11195 (200). It remains to be investigated whether the third generation of TSPO tracers shows a portion of vascular TSPO detection similarly. Moreover, further research on next generations of TSPO tracers are needed, with the selection criteria including optimal binding property, insensitivity for TSPO polymorphism, and high glial TSPO selectivity.

The role of neuroinflammation in AD pathogenesis is still not fully elucidated. Early clinical studies with first generation tracer [11C]PK11195 showed conflicting results in the brains from AD patients. Some studies demonstrated significant increases in [11C]PK11195 retention in diseased brain regions in AD (230, 231), which was not observed in some other studies (232, 233). Albrecht et al. recently reported negative associations between regional Aβ and tau PET uptake and CSF inflammatory markers in patients with AD and in non-demented controls and suggested a protective role of neuroinflammation (234). Ewers et al. showed that a higher CSF level of soluble TREM2 is indicative of microglia activation in patients with AD. The CSF level of TREM2 negatively aassociated with the rate of Aβ accumulation assessed by using [18F]florbetapir over 2-years follow-up in AD patients (101). Biphasic trajectory with an early increase and a later decline in the level of microglial activation might explain such inconsistency between results from clinical studies (62). The recently reported biphasic trajectory of astrocytosis (177) adds further complexity in the interpretation.

A recent study has showed that microglia is involved in the formation of senile plaque by promoting the diffuse form converting to dense cored form (15). In vitro immunohistochemical analysis found that TSPO-positive microglia were surrounded dense cored plaque, not diffuse plaques (235). These results may explain the complex spatial association between TSPO-PET and amyloid-PET signals. [11C]PBR28 signal correlated with both tau aggregation and Aβ deposition (55), suggesting distinct dynamic profiles of microglial activation. Collectively, current clinical studies have not provided a consensus on association between TSPO-associated neuroinflammation and AD-pathological changes. Given the different binding sites in glial and vascular TSPO for different tracers, the divergent results using different TSPO-PET tracers are not unexpected. A multitracer imaging paradigm for detecting the regional patterns of Aβ, tau, and microglia activation and astrocytosis is expected to provide better temporal and spatia mapping of disease processes and assessment of immunomodulatory therapeutic interventions in clinical study.

Several promising targets and tracers for neuroinflammation imaging have been reported but not yet been evaluated in AD patients or animal models, such as the ligands for inducible nitric oxide synthase ([18F]FBAT), reactive oxygen species ([18F]ROStrace [18F]ox-ROStrace, [18F]dihydromethidine, [11C]Ascorbic. [62Cu]ATSM, [11C]dehydroascorbic acid) (132–137), TREM-1 ([64Cu]TREM1-mAb), matrix metalloproteinases ([18F]BR-351, [18F]BR-420) (144–146), astrocyte metabolism ([11C]acetate) (171, 172), I2BS([¹⁸F]FEBU) (182), and organic anion-transporting polypeptide 1C1 ([18F]2B-SRF101) (184). More preclinical and clinical evidence are required to indicate the utilities of these emerging ligands in in vivo imaging. An almost exclusive expression of CSF1R and P2X7 receptor and P2Y12 receptor in microglia have demonstrated their potentials as next-generation imaging targets for microglia activation. Further evaluation of these tracers in amyloidosis and tauopathy models and patients with MCI and AD will potentially facilitate better phenotyping of microglia activation. The association of these emerging targets with AD pathologies, disease progression, and the improvement in the ligand binding properties and analysis methods for PET data require further investigations (236). With the advances in new techniques, e.g., single-cell analysis of neuroinflammatory responses and plasma biomarkers, the link between neuroinflammation PET with other indicators will likely be studied in a more systematic manner.

Funding

RN acknowledged the funding by Helmut Horten Stiftung, Vontobel Stiftung, UZH Entrepreneur Fellowship (reference no. MEDEF-20-021).

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Statements

Author contributions

RZ, BJ, and RN wrote the first draft and prepared the figures. All authors contributed to the article and approved the submitted version.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  • 1

    LengFEdisonP. Neuroinflammation and Microglial Activation in Alzheimer Disease: Where do We Go From Here? Nat Rev Neurol (2021) 17(3):157–72. doi: 10.1038/s41582-020-00435-y

  • 2

    RansohoffRM. How Neuroinflammation Contributes to Neurodegeneration. Science (2016) 353(6301):777. doi: 10.1126/science.aag2590

  • 3

    AllenNJLyonsDA. Glia as Architects of Central Nervous System Formation and Function. Science (2018) 362(6411):181–5. doi: 10.1126/science.aat0473

  • 4

    HenekaMTCarsonMJEl KhouryJLandrethGEBrosseronFFeinsteinDLet al. Neuroinflammation in Alzheimer’s Disease. Lancet Neurol (2015) 14(4):388–405. doi: 10.1016/s1474-4422(15)70016-5

  • 5

    HickmanSIzzySSenPMorsettLEl KhouryJ. Microglia in Neurodegeneration. Nat Neurosci (2018) 21(10):1359–69. doi: 10.1038/s41593-018-0242-x

  • 6

    GrubmanAChooXYChewGOuyangJFSunGCroftNPet al. Transcriptional Signature in Microglia Associated With Aβ Plaque Phagocytosis. Nat Commun (2021) 12(1):3015. doi: 10.1038/s41467-021-23111-1

  • 7

    SalterMWStevensB. Microglia Emerge as Central Players in Brain Disease. Nat Med (2017) 23(9):1018–27. doi: 10.1038/nm.4397

  • 8

    MathysHAdaikkanCGaoFYoungJZManetEHembergMet al. Temporal Tracking of Microglia Activation in Neurodegeneration at Single-Cell Resolution. Cell Rep (2017) 21(2):366–80. doi: 10.1016/j.celrep.2017.09.039

  • 9

    FriedmanBASrinivasanKAyalonGMeilandtWJLinHHuntleyMAet al. Diverse Brain Myeloid Expression Profiles Reveal Distinct Microglial Activation States and Aspects of Alzheimer’s Disease Not Evident in Mouse Models. Cell Rep (2018) 22(3):832–47. doi: 10.1016/j.celrep.2017.12.066

  • 10

    DeczkowskaAKeren-ShaulHWeinerAColonnaMSchwartzMAmitI. Disease-Associated Microglia: A Universal Immune Sensor of Neurodegeneration. Cell (2018) 173(5):1073–81. doi: 10.1016/j.cell.2018.05.003

  • 11

    Keren-ShaulHSpinradAWeinerAMatcovitch-NatanODvir-SzternfeldRUllandTKet al. A Unique Microglia Type Associated With Restricting Development of Alzheimer’s Disease. Cell (2017) 169(7):1276–90.e17. doi: 10.1016/j.cell.2017.05.018

  • 12

    SongWMColonnaM. The Identity and Function of Microglia in Neurodegeneration. Nat Immunol (2018) 19(10):1048–58. doi: 10.1038/s41590-018-0212-1

  • 13

    LengKLiEEserRPiergiesASitRTanMet al. Molecular Characterization of Selectively Vulnerable Neurons in Alzheimer’s Disease. Nat Neurosci (2021) 24(2):276–87. doi: 10.1038/s41593-020-00764-7

  • 14

    ParhizkarSArzbergerTBrendelMKleinbergerGDeussingMFockeCet al. Loss of TREM2 Function Increases Amyloid Seeding But Reduces Plaque-Associated ApoE. Nat Neurosci (2019) 22(2):191–204. doi: 10.1038/s41593-018-0296-9

  • 15

    HuangYHapponenKEBurrolaPGO’ConnorCHahNHuangLet al. Microglia Use TAM Receptors to Detect and Engulf Amyloid β Plaques. Nat Immunol (2021) 22(5):586–94. doi: 10.1038/s41590-021-00913-5

  • 16

    LiddelowSAGuttenplanKAClarkeLEBennettFCBohlenCJSchirmerLet al. Neurotoxic Reactive Astrocytes are Induced by Activated Microglia. Nature (2017) 541(7638):481–7. doi: 10.1038/nature21029

  • 17

    LiTLiuTChenXLiLFengMZhangYet al. Microglia Induce the Transformation of A1/A2 Reactive Astrocytes via the CXCR7/PI3K/Akt Pathway in Chronic Post-Surgical Pain. J Neuroinflamm (2020) 17(1):211. doi: 10.1186/s12974-020-01891-5

  • 18

    EscartinCGaleaELakatosAO’CallaghanJPPetzoldGCSerrano-PozoAet al. Reactive Astrocyte Nomenclature, Definitions, and Future Directions. Nat Neurosci (2021) 24(3):312–25. doi: 10.1038/s41593-020-00783-4

  • 19

    ClarkeLELiddelowSAChakrabortyCMünchAEHeimanMBarresBA. Normal Aging Induces A1-Like Astrocyte Reactivity. Proc Natl Acad Sci (2018) 115(8):E1896. doi: 10.1073/pnas.1800165115

  • 20

    ChunHImHKangYJKimYShinJHWonWet al. Severe Reactive Astrocytes Precipitate Pathological Hallmarks of Alzheimer’s Disease via H(2)O(2)(-) Production. Nat Neurosci (2020) 23(12):1555–66. doi: 10.1038/s41593-020-00735-y

  • 21

    KovacsGGFerrerIGrinbergLTAlafuzoffIAttemsJBudkaHet al. Aging-Related Tau Astrogliopathy (ARTAG): Harmonized Evaluation Strategy. Acta Neuropathol (2016) 131(1):87–102. doi: 10.1007/s00401-015-1509-x

  • 22

    HabibNMcCabeCMedinaSVarshavskyMKitsbergDDvir-SzternfeldRet al. Disease-Associated Astrocytes in Alzheimer’s Disease and Aging. Nat Neurosci (2020) 23(6):701–6. doi: 10.1038/s41593-020-0624-8

  • 23

    ElahiFMCasalettoKBLa JoieRWaltersSMHarveyDWolfAet al. Plasma Biomarkers of Astrocytic and Neuronal Dysfunction in Early- and Late-Onset Alzheimer’s Disease. Alzheimers Dement (2020) 16(4):681–95. doi: 10.1016/j.jalz.2019.09.004

  • 24

    ChatterjeePPedriniSStoopsEGoozeeKVillemagneVLAsihPRet al. Plasma Glial Fibrillary Acidic Protein is Elevated in Cognitively Normal Older Adults at Risk of Alzheimer’s Disease. Trans Psychiatry (2021) 11(1):27. doi: 10.1038/s41398-020-01137-1

  • 25

    VerberkIMWThijssenEKoelewijnJMaurooKVanbrabantJde WildeAet al. Combination of Plasma Amyloid Beta((1-42/1-40)) and Glial Fibrillary Acidic Protein Strongly Associates With Cerebral Amyloid Pathology. Alzheimers Res Ther (2020) 12(1):118. doi: 10.1186/s13195-020-00682-7

  • 26

    IshikawaATokunagaMMaedaJMinamihisamatsuTShimojoMTakuwaHet al. In Vivo Visualization of Tau Accumulation, Microglial Activation, and Brain Atrophy in a Mouse Model of Tauopathy Rtg4510. J Alzheimers Dis (2018) 61(3):1037–52. doi: 10.3233/jad-170509

  • 27

    NiRJiBOnoMSaharaNZhangMRAokiIet al. Comparative in-Vitro and in-Vivo Quantifications of Pathological Tau Deposits and Their Association With Neurodegeneration in Tauopathy Mouse Models. J Nucl Med (2018) 59(6):960–6. doi: 10.2967/jnumed.117.201632

  • 28

    VillemagneVLDoreVBurnhamSCMastersCLRoweCC. Imaging Tau and Amyloid-Beta Proteinopathies in Alzheimer Disease and Other Conditions. Nat Rev Neurol (2018) 14(4):225–36. doi: 10.1038/nrneurol.2018.9

  • 29

    TagaiKOnoMKubotaMKitamuraSTakahataKSekiCet al. High-Contrast In Vivo Imaging of Tau Pathologies in Alzheimer’s and Non-Alzheimer’s Disease Tauopathies. Neuron (2021) 109(1):42–58.e8. doi: 10.1016/j.neuron.2020.09.042

  • 30

    DuboisBVillainNFrisoniGBRabinoviciGDSabbaghMCappaSet al. Clinical Diagnosis of Alzheimer’s Disease: Recommendations of the International Working Group. Lancet Neurol (2021) 20(6):484–96. doi: 10.1016/S1474-4422(21)00066-1

  • 31

    RazanskyDKlohsJNiR. Multi-Scale Optoacoustic Molecular Imaging of Brain Diseases. Eur J Nucl Med Mol Imaging (2021). doi: 10.1007/s00259-021-05207-4

  • 32

    KreislWCKimMJCoughlinJMHenterIDOwenDRInnisRB. PET Imaging of Neuroinflammation in Neurological Disorders. Lancet Neurol (2020) 19(11):940–50. doi: 10.1016/s1474-4422(20)30346-x

  • 33

    NiRDean-BenXLKirschenbaumDRudinMChenZCrimiAet al. Whole Brain Optoacoustic Tomography Reveals Strain-Specific Regional Beta-Amyloid Densities in Alzheimer`s Disease Amyloidosis Models. bioRxiv (2020). doi: 10.1101/2020.02.25.964064

  • 34

    NiRRudinMKlohsJ. Cortical Hypoperfusion and Reduced Cerebral Metabolic Rate of Oxygen in the Arcabeta Mouse Model of Alzheimer’s Disease. Photoacoustics (2018) 10:38–47. doi: 10.1016/j.pacs.2018.04.001

  • 35

    OnoMSaharaNKumataKJiBNiRQKogaSet al. Distinct Binding of PET Ligands PBB3 and AV-1451 to Tau Fibril Strains in Neurodegenerative Tauopathies. Brain (2017) 140:764–80. doi: 10.1093/brain/aww339

  • 36

    LuziFSavickasVTaddeiCHaderSSinghNGeeADet al. Radiolabeling of [(11)C]FPS-ZM1, a Receptor for Advanced Glycation End Products-Targeting Positron Emission Tomography Radiotracer, Using a [(11)C]CO(2)-To-[(11)C]CO Chemical Conversion. Future Med Chem (2020) 12(6):511–21. doi: 10.4155/fmc-2019-0329

  • 37

    ParboPIsmailRHansenKVAmidiAMårupFHGottrupHet al. Brain Inflammation Accompanies Amyloid in the Majority of Mild Cognitive Impairment Cases Due to Alzheimer’s Disease. Brain (2017) 140(7):2002–11. doi: 10.1093/brain/awx120

  • 38

    MalpettiMKievitRAPassamontiLJonesPSTsvetanovKARittmanTet al. Microglial Activation and Tau Burden Predict Cognitive Decline in Alzheimer’s Disease. Brain (2020) 143(5):1588–602. doi: 10.1093/brain/awaa088

  • 39

    NicastroNMalpettiMMakEWilliamsGBBevan-JonesWRCarterSFet al. Gray Matter Changes Related to Microglial Activation in Alzheimer’s Disease. Neurobiol Aging (2020) 94:236–42. doi: 10.1016/j.neurobiolaging.2020.06.010

  • 40

    FanZBrooksDJOkelloAEdisonP. An Early and Late Peak in Microglial Activation in Alzheimer’s Disease Trajectory. Brain J Neurol (2017) 140(3):792–803. doi: 10.1093/brain/aww349

  • 41

    IsmailRParboPMadsenLSHansenAKHansenKVSchaldemoseJLet al. The Relationships Between Neuroinflammation, Beta-Amyloid and Tau Deposition in Alzheimer’s Disease: A Longitudinal PET Study. J Neuroinflamm (2020) 17(1):151. doi: 10.1186/s12974-020-01820-6

  • 42

    SuLSurendranathanAHuangYBevan-JonesWRPassamontiLHongYTet al. Relationship Between Tau, Neuroinflammation and Atrophy in Alzheimer’s Disease: The NIMROD Study. Inf Fusion (2021) 67:116–24. doi: 10.1016/j.inffus.2020.10.006

  • 43

    PassamontiLRodríguezPVHongYTAllinsonKSJBevan-JonesWRWilliamsonDet al. [11c]PK11195 Binding in Alzheimer Disease and Progressive Supranuclear Palsy. Neurology (2018) 90(22):e1989. doi: 10.1212/WNL.0000000000005610

  • 44

    ChiquitaSRibeiroMCastelhanoJOliveiraFSerenoJBatistaMet al. A Longitudinal Multimodal In Vivo Molecular Imaging Study of the 3xtg-AD Mouse Model Shows Progressive Early Hippocampal and Taurine Loss. Hum Mol Genet (2019) 28(13):2174–88. doi: 10.1093/hmg/ddz045

  • 45

    HamelinLLagardeJDorothéeGPotierMCCorlierFKuhnastBet al. Distinct Dynamic Profiles of Microglial Activation Are Associated With Progression of Alzheimer’s Disease. Brain (2018) 141(6):1855–70. doi: 10.1093/brain/awy079

  • 46

    HagensMHJGollaSVWijburgMTYaqubMHeijtelDSteenwijkMDet al. In Vivo Assessment of Neuroinflammation in Progressive Multiple Sclerosis: A Proof of Concept Study With [(18)F]DPA714 PET. J Neuroinflamm (2018) 15(1):314. doi: 10.1186/s12974-018-1352-9

  • 47

    HuWPanDWangYBaoWZuoCGuanYet al. PET Imaging for Dynamically Monitoring Neuroinflammation in APP/PS1 Mouse Model Using [(18)F]Dpa714. Front Neurosci (2020) 14:810. doi: 10.3389/fnins.2020.00810

  • 48

    ChaneyABauerMBochicchioDSmigovaAKassiouMDaviesKEet al. Longitudinal Investigation of Neuroinflammation and Metabolite Profiles in the APP(swe) ×Ps1(Δe9) Transgenic Mouse Model of Alzheimer’s Disease. J Neurochem (2018) 144(3):318–35. doi: 10.1111/jnc.14251

  • 49

    SérrièreSTauberCVercouillieJMothesCPrucknerCGuilloteauDet al. Amyloid Load and Translocator Protein 18 kDa in APPswePS1-De9 Mice: A Longitudinal Study. Neurobiol Aging (2015) 36(4):1639–52. doi: 10.1016/j.neurobiolaging.2014.11.023

  • 50

    ChaneyAMLopez-PiconFRSerrièreSWangRBochicchioDWebbSDet al. Prodromal Neuroinflammatory, Cholinergic and Metabolite Dysfunction Detected by PET and MRS in the TgF344-AD Transgenic Rat Model of AD: A Collaborative Multi-Modal Study. Theranostics (2021) 11(14):6644–67. doi: 10.7150/thno.56059

  • 51

    TakkinenJSLópez-PicónFRAl MajidiREskolaOKrzyczmonikAKellerTet al. Brain Energy Metabolism and Neuroinflammation in Ageing APP/PS1-21 Mice Using Longitudinal (18)F-FDG and (18)F-DPA-714 PET Imaging. J Cereb Blood Flow Metab (2017) 37(8):2870–82. doi: 10.1177/0271678x16677990

  • 52

    YokokuraMTeradaTBunaiTNakaizumiKTakebayashiKIwataYet al. Depiction of Microglial Activation in Aging and Dementia: Positron Emission Tomography With [(11)C]DPA713 Versus [(11)C](R)Pk11195. J Cereb Blood Flow Metab (2017) 37(3):877–89. doi: 10.1177/0271678x16646788

  • 53

    ChaneyACropperHCJohnsonEMLechtenbergKJPetersonTCStevensMYet al. (11)C-DPA-713 Versus (18)F-GE-180: A Preclinical Comparison of Translocator Protein 18 kDa PET Tracers to Visualize Acute and Chronic Neuroinflammation in a Mouse Model of Ischemic Stroke. J Nucl Med (2019) 60(1):122–8. doi: 10.2967/jnumed.118.209155

  • 54

    TsukadaHNishiyamaSOhbaHKanazawaMKakiuchiTHaradaN. Comparing Amyloid-β Deposition, Neuroinflammation, Glucose Metabolism, and Mitochondrial Complex I Activity in Brain: A PET Study in Aged Monkeys. Eur J Nucl Med Mol Imaging (2014) 41(11):2127–36. doi: 10.1007/s00259-014-2821-8

  • 55

    KellerTLópez-PicónFRKrzyczmonikAForsbackSTakkinenJSRajanderJet al. Comparison of High and Low Molar Activity TSPO Tracer [(18)F]F-DPA in a Mouse Model of Alzheimer’s Disease. J Cereb Blood Flow Metab (2020) 40(5):1012–20. doi: 10.1177/0271678x19853117

  • 56

    FairleyLHSaharaNAokiIJiBSuharaTHiguchiMet al. Neuroprotective Effect of Mitochondrial Translocator Protein Ligand in a Mouse Model of Tauopathy. J Neuroinflamm (2021) 18(1):76. doi: 10.1186/s12974-021-02122-1

  • 57

    JiBOnoMYamasakiTFujinagaMZhangMRSekiCet al. Detection of Alzheimer’s Disease-Related Neuroinflammation by a PET Ligand Selective for Glial Versus Vascular Translocator Protein. J Cereb Blood Flow Metab (2021) 41(8):2076–89. doi: 10.1177/0271678x21992457

  • 58

    BarronAMJiBFujinagaMZhangMRSuharaTSaharaNet al. In Vivo Positron Emission Tomography Imaging of Mitochondrial Abnormalities in a Mouse Model of Tauopathy. Neurobiol Aging (2020) 94:140–8. doi: 10.1016/j.neurobiolaging.2020.05.003

  • 59

    JiBMaedaJSawadaMOnoMOkauchiTInajiMet al. Imaging of Peripheral Benzodiazepine Receptor Expression as Biomarkers of Detrimental Versus Beneficial Glial Responses in Mouse Models of Alzheimer’s and Other CNS Pathologies. J Neurosci (2008) 28(47):12255–67. doi: 10.1523/jneurosci.2312-08.2008

  • 60

    MaedaJZhangMROkauchiTJiBOnoMHattoriSet al. In Vivo Positron Emission Tomographic Imaging of Glial Responses to Amyloid-Beta and Tau Pathologies in Mouse Models of Alzheimer’s Disease and Related Disorders. J Neurosci (2011) 31(12):4720–30. doi: 10.1523/jneurosci.3076-10.2011

  • 61

    NiRRöjdnerJVoytenkoLDyrksTThieleAMarutleAet al. In Vitro Characterization of the Regional Binding Distribution of Amyloid PET Tracer Florbetaben and the Glia Tracers Deprenyl and PK1195 in Autopsy Alzheimer’s Brain Tissue. J Alzheimer’s Dis (2021) 80(4):1723–37. doi: 10.3233/JAD-201344

  • 62

    VarroneAOikonenVForsbergAJoutsaJTakanoASolinOet al. Positron Emission Tomography Imaging of the 18-kDa Translocator Protein (TSPO) With [18F]FEMPA in Alzheimer’s Disease Patients and Control Subjects. Eur J Nucl Med Mol Imaging (2015) 42(3):438–46. doi: 10.1007/s00259-014-2955-8

  • 63

    MiyoshiMItoHArakawaRTakahashiHTakanoHHiguchiMet al. Quantitative Analysis of Peripheral Benzodiazepine Receptor in the Human Brain Using PET With 11C-AC-5216. J Nucl Med (2009) 50(7):1095. doi: 10.2967/jnumed.109.062554

  • 64

    ZhouXJiBSekiCNagaiYMinamimotoTFujinagaMet al. PET Imaging of Colony-Stimulating Factor 1 Receptor: A Head-to-Head Comparison of a Novel Radioligand, (11)C-GW2580, and (11)C-CPPC, in Mouse Models of Acute and Chronic Neuroinflammation and a Rhesus Monkey. J Cereb Blood Flow Metab (2021) 41(9):2410–22. doi: 10.1177/0271678x211004146

  • 65

    TakuwaHOriharaATakadoYUrushihataTShimojoMIshikawaAet al. Tracking Tau Fibrillogenesis and Consequent Primary Phagocytosis of Neurons Mediated by Microglia in a Living Tauopathy Model. bioRxiv (2020) 2020.11.04.368977. doi: 10.1101/2020.11.04.368977

  • 66

    SuridjanIPollockBGVerhoeffNPVoineskosANChowTRusjanPMet al. In-Vivo Imaging of Grey and White Matter Neuroinflammation in Alzheimer’s Disease: A Positron Emission Tomography Study With a Novel Radioligand, [18F]-FEPPA. Mol Psychiatry (2015) 20(12):1579–87. doi: 10.1038/mp.2015.1

  • 67

    KnezevicDVerhoeffNPLHafiziSStrafellaAPGraff-GuerreroARajjiTet al. Imaging Microglial Activation and Amyloid Burden in Amnestic Mild Cognitive Impairment. J Cereb Blood Flow Metab (2018) 38(11):1885–95. doi: 10.1177/0271678x17741395

  • 68

    Al-KhishmanNUQiQRoseboroughADLevitAAllmanBLAnazodoUCet al. TSPO PET Detects Acute Neuroinflammation But Not Diffuse Chronically Activated MHCII Microglia in the Rat. EJNMMI Res (2020) 10(1):113. doi: 10.1186/s13550-020-00699-x

  • 69

    DaniMWoodMMizoguchiRFanZWalkerZMorganRet al. Microglial Activation Correlates In Vivo With Both Tau and Amyloid in Alzheimer’s Disease. Brain (2018) 141(9):2740–54. doi: 10.1093/brain/awy188

  • 70

    GiridharanVVCollodelAGenerosoJSScainiGWassatherRSelvarajSet al. Neuroinflammation Trajectories Precede Cognitive Impairment After Experimental Meningitis-Evidence From an In Vivo PET Study. J Neuroinflamm (2020) 17(1):5. doi: 10.1186/s12974-019-1692-0

  • 71

    ToppalaSEkbladLLTuiskuJHelinSJohanssonJJLaineHet al. Association of Early β-Amyloid Accumulation and Neuroinflammation Measured With [(11)C]PBR28 in Elderly Individuals Without Dementia. Neurology (2021) 96(12):e1608–19. doi: 10.1212/wnl.0000000000011612

  • 72

    JamesMLBelichenkoNPNguyenTVAndrewsLEDingZLiuHet al. PET Imaging of Translocator Protein (18 kDa) in a Mouse Model of Alzheimer’s Disease Using N-(2,5-Dimethoxybenzyl)-2-18F-Fluoro-N-(2-Phenoxyphenyl)Acetamide. J Nucl Med (2015) 56(2):311–6. doi: 10.2967/jnumed.114.141648

  • 73

    MirzaeiNTangSPAshworthSCoelloCPlissonCPasschierJet al. In Vivo Imaging of Microglial Activation by Positron Emission Tomography With [(11)C]PBR28 in the 5XFAD Model of Alzheimer’s Disease. Glia (2016) 64(6):993–1006. doi: 10.1002/glia.22978

  • 74

    ZouJTaoSJohnsonATomljanovicZPollyKKleinJet al. Microglial Activation, But Not Tau Pathology, is Independently Associated With Amyloid Positivity and Memory Impairment. Neurobiol Aging (2020) 85:11–21. doi: 10.1016/j.neurobiolaging.2019.09.019

  • 75

    Zanotti-FregonaraPPascualBVeroneseMYuMBeersDAppelSHet al. Head-To-Head Comparison of (11)C-PBR28 and (11)C-ER176 for Quantification of the Translocator Protein in the Human Brain. Eur J Nucl Med Mol Imaging (2019) 46(9):1822–9. doi: 10.1007/s00259-019-04349-w

  • 76

    Zanotti-FregonaraPPascualBRizzoGYuMPalNBeersDet al. Head-To-Head Comparison of (11)C-PBR28 and (18)F-GE180 for Quantification of the Translocator Protein in the Human Brain. J Nucl Med (2018) 59(8):1260–6. doi: 10.2967/jnumed.117.203109

  • 77

    PascualBFunkQZanotti-FregonaraPCykowskiMDVeroneseMRockersEet al. Neuroinflammation is Highest in Areas of Disease Progression in Semantic Dementia. Brain (2021) 44(5):1565–75. doi: 10.1093/brain/awab057

  • 78

    WalkerMDDinelleKKornelsenRLeeNVMiaoQAdamMet al. [11c]PBR28 PET Imaging is Sensitive to Neuroinflammation in the Aged Rat. J Cereb Blood Flow Metab (2015) 35(8):1331–8. doi: 10.1038/jcbfm.2015.54

  • 79

    SchainMZanderigoFOgdenRTKreislWC. Non-Invasive Estimation of [(11)C]PBR28 Binding Potential. Neuroimage (2018) 169:278–85. doi: 10.1016/j.neuroimage.2017.12.002

  • 80

    DonatCKMirzaeiNTangSPEdisonPSastreM. Imaging of Microglial Activation in Alzheimer’s Disease by [(11)C]PBR28 PET. Methods Mol Biol (2018) 1750:323–39. doi: 10.1007/978-1-4939-7704-8_22

  • 81

    XuJSunJPerrinRJMachRHBalesKRMorrisJCet al. Translocator Protein in Late Stage Alzheimer’s Disease and Dementia With Lewy Bodies Brains. Ann Clin Transl Neurol (2019) 6(8):1423–34. doi: 10.1002/acn3.50837

  • 82

    KimMJMcGwierMJenkoKJSnowJMorseCZoghbiSSet al. Neuroinflammation in Frontotemporal Lobar Degeneration Revealed by (11) C-PBR28 PET. Ann Clin Transl Neurol (2019) 6(7):1327–31. doi: 10.1002/acn3.50802

  • 83

    EberlSKatsifisAPeyronneauMAWenLHendersonDLoc’hCet al. Preclinical In Vivo and In Vitro Comparison of the Translocator Protein PET Ligands [(18)F]PBR102 and [(18)F]PBR111. Eur J Nucl Med Mol Imaging (2017) 44(2):296–307. doi: 10.1007/s00259-016-3517-z

  • 84

    DeleyeSWaldronAMVerhaegheJBottelbergsAWyffelsLVan BroeckBet al. Evaluation of Small-Animal PET Outcome Measures to Detect Disease Modification Induced by BACE Inhibition in a Transgenic Mouse Model of Alzheimer Disease. J Nucl Med (2017) 58(12):1977–83. doi: 10.2967/jnumed.116.187625

  • 85

    TournierBBTsartsalisSCeyzériatKFraserBHGrégoireMCKövariEet al. Astrocytic TSPO Upregulation Appears Before Microglial TSPO in Alzheimer’s Disease. J Alzheimers Dis (2020) 77(3):1043–56. doi: 10.3233/jad-200136

  • 86

    TournierBBTsartsalisSRigaudDFosseyCCaillyTFabisFet al. TSPO and Amyloid Deposits in Sub-Regions of the Hippocampus in the 3xtgad Mouse Model of Alzheimer’s Disease. Neurobiol Dis (2019) 121:95–105. doi: 10.1016/j.nbd.2018.09.022

  • 87

    SzöllősiDHegedűsNVeresDSFutóIHorváthIKovácsNet al. Evaluation of Brain Nuclear Medicine Imaging Tracers in a Murine Model of Sepsis-Associated Encephalopathy. Mol Imaging Biol (2018) 20(6):952–62. doi: 10.1007/s11307-018-1201-3

  • 88

    VettermannFHarrisSSchmittJUnterrainerMLindnerSRauchmannB-Set al. Impact of TSPO Receptor Polymorphism on [18F]GE-180 Binding in Healthy Brain and Pseudo-Reference Regions of Neurooncological and Neurodegenerative Disorders. Life (2021) 11:484. doi: 10.3390/life11060484

  • 89

    PalleisCSauerbeckJBeyerLHarrisSSchmittJMorenas-RodriguezEet al. In Vivo Assessment of Neuroinflammation in 4-Repeat Tauopathies. Mov Disord (2021) 36(4):883–94. doi: 10.1002/mds.28395

  • 90

    López-PicónFRSnellmanAEskolaOHelinSSolinOHaaparanta-SolinMet al. Neuroinflammation Appears Early on PET Imaging and Then Plateaus in a Mouse Model of Alzheimer Disease. J Nucl Med (2018) 59(3):509. doi: 10.2967/jnumed.117.197608

  • 91

    KaiserLAlbertNLindnerSUnterrainerMMahlerCBrendelMet al. TSPO Imaging Using the Novel PET Ligand [18F]GE-180: Quantification Approaches in Patients With Multiple Sclerosis. EJNMMI Res7(2017) 45(8):1423–31. doi: 10.1186/s13550-017-0340-x

  • 92

    LiuBLeKXParkMAWangSBelangerAPDubeySet al. In Vivo Detection of Age- and Disease-Related Increases in Neuroinflammation by 18F-GE180 TSPO MicroPET Imaging in Wild-Type and Alzheimer’s Transgenic Mice. J Neurosci (2015) 35(47):15716–30. doi: 10.1523/jneurosci.0996-15.2015

  • 93

    BlumeTFockeCPetersFDeussingMAlbertNLLindnerSet al. Microglial Response to Increasing Amyloid Load Saturates With Aging: A Longitudinal Dual Tracer In Vivo μpet-Study. J Neuroinflamm (2018) 15(1):307. doi: 10.1186/s12974-018-1347-6

  • 94

    JamesMLBelichenkoNPShuhendlerAJHoehneAAndrewsLECondonCet al. [(18)F]GE-180 PET Detects Reduced Microglia Activation After LM11A-31 Therapy in a Mouse Model of Alzheimer’s Disease. Theranostics (2017) 7(6):1422–36. doi: 10.7150/thno.17666

  • 95

    BiecheleGWindKBlumeTSacherCBeyerLEckenweberFet al. Microglial Activation in the Right Amygdala-Entorhinal-Hippocampal Complex Is Associated With Preserved Spatial Learning in App(NL-G-F) Mice. Neuroimage (2021) 230:117707. doi: 10.1016/j.neuroimage.2020.117707

  • 96

    SacherCBlumeTBeyerLBiecheleGSauerbeckJEckenweberFet al. Asymmetry of Fibrillar Plaque Burden in Amyloid Mouse Models. J Nucl Med (2020) 61(12):1825–31. doi: 10.2967/jnumed.120.242750

  • 97

    KleinbergerGBrendelMMracskoEWefersBGroenewegLXiangXet al. The FTD-Like Syndrome Causing TREM2 T66M Mutation Impairs Microglia Function, Brain Perfusion, and Glucose Metabolism. EMBO J (2017) 36(13):1837–53. doi: 10.15252/embj.201796516

  • 98

    EckenweberFMedina-LuqueJBlumeTSacherCBiecheleGWindKet al. Longitudinal TSPO Expression in Tau Transgenic P301S Mice Predicts Increased Tau Accumulation and Deteriorated Spatial Learning. J Neuroinflamm (2020) 17(1):208. doi: 10.1186/s12974-020-01883-5

  • 99

    BiecheleGBlumeTDeussingMZottBShiYXiangXet al. Pre-Therapeutic Microglia Activation and Sex Determine Therapy Effects of Chronic Immunomodulation. bioRxiv (2021). doi: 10.1101/2021.05.30.445761

  • 100

    LiuBHinshawRGLeKXParkM-AWangSBelangerAPet al. Space-Like 56Fe Irradiation Manifests Mild, Early Sex-Specific Behavioral and Neuropathological Changes in Wildtype and Alzheimer’s-Like Transgenic Mice. Sci Rep (2019) 9(1):12118. doi: 10.1038/s41598-019-48615-1

  • 101

    EwersMBiecheleGSuárez-CalvetMSacherCBlumeTMorenas-RodriguezEet al. Higher CSF Strem2 and Microglia Activation are Associated With Slower Rates of Beta-Amyloid Accumulation. EMBO Mol Med (2020) 12(9):e12308. doi: 10.15252/emmm.202012308

  • 102

    BoutinHMurrayKPradilloJMaroyRSmigovaAGerhardAet al. 18f-GE-180: A Novel TSPO Radiotracer Compared to 11C-R-PK11195 in a Preclinical Model of Stroke. Eur J Nucl Med Mol Imaging (2015) 42(3):503–11. doi: 10.1007/s00259-014-2939-8

  • 103

    RamakrishnanNKHirdMThompsonSWilliamsonDJQiaoLOwenDRet al. Preclinical Evaluation of (S)-[18f]GE387, a Novel 18-kDa Translocator Protein (TSPO) PET Radioligand With Low Binding Sensitivity to Human Polymorphism Rs6971. Eur J Nucl Med Mol Imaging (2021). doi: 10.1007/s00259-021-05495-w

  • 104

    QiaoLFisherEMcMurrayLMilicevic SephtonSHirdMKuzhuppilly-RamakrishnanNet al. Radiosynthesis of (R,S)-[(18) F]GE387: A Potential PET Radiotracer for Imaging Translocator Protein 18 kDa (TSPO) With Low Binding Sensitivity to the Human Gene Polymorphism Rs6971. ChemMedChem (2019) 14(9):982–93. doi: 10.1002/cmdc.201900023

  • 105

    IkawaMLohithTGShresthaSTeluSZoghbiSSCastellanoSet al. 11c-ER176, a Radioligand for 18-kDa Translocator Protein, Has Adequate Sensitivity to Robustly Image All Three Affinity Genotypes in Human Brain. J Nucl Med Off Publ Soc Nucl Med (2017) 58(2):320–5. doi: 10.2967/jnumed.116.178996

  • 106

    FujitaMKobayashiMIkawaMGunnRNRabinerEAOwenDRet al. Comparison of Four 11C-Labeled PET Ligands to Quantify Translocator Protein 18 kDa (TSPO) in Human Brain: (R)-PK11195, PBR28, DPA-713, and ER176—based on Recent Publications That Measured Specific-to-non-Displaceable Ratios. EJNMMI Res (2017) 7(1):84. doi: 10.1186/s13550-017-0334-8

  • 107

    HatanoKSekimataKYamadaTAbeJItoKOgawaMet al. Radiosynthesis and In Vivo Evaluation of Two Imidazopyridineacetamides, [11C]CB184 and [11C]CB190, as a PET Tracer for 18 kDa Translocator Protein: Direct Comparison With [11C](R)-Pk11195. Ann Nucl Med (2015) 29(4):325–35. doi: 10.1007/s12149-015-0948-8

  • 108

    TiwariAKZhangYYamasakiTKumariNFujinagaMMoriWet al. Radiosynthesis and Evaluation of Acetamidobenzoxazolone Based Radioligand [11C]N′-MPB for Visualization of 18 kDa TSPO in Brain. New J Chem (2020) 44(19):7912–22. doi: 10.1039/D0NJ00509F

  • 109

    MacAskillMGStadulyteAWilliamsLMorganTEFSloanNLAlcaide-CorralCJet al. Quantification of Macrophage-Driven Inflammation During Myocardial Infarction With 18F-LW223, a Novel TSPO Radiotracer With Binding Independent of the Rs6971 Human Polymorphism. J Nucl Med (2021) 62(4):536. doi: 10.2967/jnumed.120.243600

  • 110

    HanJLiuHLiuCJinHPerlmutterJSEganTMet al. Pharmacologic Characterizations of a P2X7 Receptor-Specific Radioligand, [11C]GSK1482160 for Neuroinflammatory Response. Nucl Med Commun (2017) 38(5):372–82. doi: 10.1097/mnm.0000000000000660

  • 111

    TerritoPRMeyerJAPetersJSRileyAAMcCarthyBPGaoMet al. Characterization of (11)C-GSK1482160 for Targeting the P2X7 Receptor as a Biomarker for Neuroinflammation. J Nucl Med (2017) 58(3):458–65. doi: 10.2967/jnumed.116.181354

  • 112

    KooleMSchmidtMEHijzenARavenstijnPVandermeulenCVan WeehaegheDet al. (18)F-JNJ-64413739, a Novel PET Ligand for the P2X7 Ion Channel: Radiation Dosimetry, Kinetic Modeling, Test-Retest Variability, and Occupancy of the P2X7 Antagonist JNJ-54175446. J Nucl Med (2019) 60(5):683–90. doi: 10.2967/jnumed.118.216747

  • 113

    Van WeehaegheDVan SchoorEDe VochtJKooleMAttiliBCelenSet al. TSPO Versus P2X7 as a Target for Neuroinflammation: An In Vitro and In Vivo Study. J Nucl Med (2020) 61(4):604–7. doi: 10.2967/jnumed.119.231985

  • 114

    BerdyyevaTXiaCTaylorNHeYChenGHuangCet al. PET Imaging of the P2X7 Ion Channel With a Novel Tracer [(18)F]JNJ-64413739 in a Rat Model of Neuroinflammation. Mol Imaging Biol (2019) 21(5):871–8. doi: 10.1007/s11307-018-01313-2

  • 115

    OryDCelenSGijsbersRVan Den HauteCPostnovAKooleMet al. Preclinical Evaluation of a P2X7 Receptor-Selective Radiotracer: PET Studies in a Rat Model With Local Overexpression of the Human P2X7 Receptor and in Nonhuman Primates. J Nucl Med (2016) 57(9):1436–41. doi: 10.2967/jnumed.115.169995

  • 116

    CrabbéMvan der PerrenABollaertsIKounelisSBaekelandtVBormansGet al. Increased P2X7 Receptor Binding Is Associated With Neuroinflammation in Acute But Not Chronic Rodent Models for Parkinson’s Disease. Front Neurosci (2019) 13:799. doi: 10.3389/fnins.2019.00799

  • 117

    HagensMHJGollaSSVJanssenBVugtsDJBeainoWWindhorstADet al. The P2X7 Receptor Tracer [11C]SMW139 as an In Vivo Marker of Neuroinflammation in Multiple Sclerosis: A First-in Man Study. Eur J Nucl Med Mol Imaging (2020) 47(2):379–89. doi: 10.1007/s00259-019-04550-x

  • 118

    BeainoWJanssenBKooijmanEVosRSchuitRCO’Brien-BrownJet al. PET Imaging of P2X7R in the Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis Using [11C]SMW139. J Neuroinflamm (2020) 17(1):300. doi: 10.1186/s12974-020-01962-7

  • 119

    JanssenBVugtsDJWilkinsonSMOryDChalonSHoozemansJJMet al. Identification of the Allosteric P2X7 Receptor Antagonist [11C]SMW139 as a PET Tracer of Microglial Activation. Sci Rep (2018) 8(1):6580. doi: 10.1038/s41598-018-24814-0

  • 120

    BeainoWJanssenBKooijGvan der PolSMAvan Het HofBvan HorssenJet al. Purinergic Receptors P2Y12R and P2X7R: Potential Targets for PET Imaging of Microglia Phenotypes in Multiple Sclerosis. J Neuroinflamm (2017) 14(1):259. doi: 10.1186/s12974-017-1034-z

  • 121

    JanssenBVugtsDJFunkeUSpaansASchuitRCKooijmanEet al. Synthesis and Initial Preclinical Evaluation of the P2X7 Receptor Antagonist [¹¹C]A-740003 as a Novel Tracer of Neuroinflammation. J Labelled Comp Radiopharm (2014) 57(8):509–16. doi: 10.1002/jlcr.3206

  • 122

    VillaAKleinBJanssenBPedragosaJPepeGZinnhardtBet al. Identification of New Molecular Targets for PET Imaging of the Microglial Anti-Inflammatory Activation State. Theranostics (2018) 8(19):5400–18. doi: 10.7150/thno.25572

  • 123

    MaedaJMinamihisamatsuTShimojoMZhouXOnoMMatsubaYet al. Distinct Microglial Response Against Alzheimer’s Amyloid and Tau Pathologies Characterized by P2Y12 Receptor. Brain Commun (2021) 3(1):fcab011. doi: 10.1093/braincomms/fcab011

  • 124

    HortiAGNaikRFossCAMinnIMishenevaVDuYet al. PET Imaging of Microglia by Targeting Macrophage Colony-Stimulating Factor 1 Receptor (CSF1R). Proc Natl Acad Sci USA (2019) 116(5):1686–91. doi: 10.1073/pnas.1812155116

  • 125

    OhnishiASendaMYamaneTSasakiMMikamiTNishioTet al. Human Whole-Body Biodistribution and Dosimetry of a New PET Tracer, [(11)C]ketoprofen Methyl Ester, for Imagings of Neuroinflammation. Nucl Med Biol (2014) 41(7):594–9. doi: 10.1016/j.nucmedbio.2014.04.008

  • 126

    OhnishiASendaMYamaneTMikamiTNishidaHNishioTet al. Exploratory Human PET Study of the Effectiveness of (11)C-Ketoprofen Methyl Ester, a Potential Biomarker of Neuroinflammatory Processes in Alzheimer’s Disease. Nucl Med Biol (2016) 43(7):438–44. doi: 10.1016/j.nucmedbio.2016.04.005

  • 127

    ShukuriMMawatariAOhnoMSuzukiMDoiHWatanabeYet al. Detection of Cyclooxygenase-1 in Activated Microglia During Amyloid Plaque Progression: PET Studies in Alzheimer’s Disease Model Mice. J Nucl Med (2016) 57(2):291–6. doi: 10.2967/jnumed.115.166116

  • 128

    ShresthaSSinghPCortes-SalvaMYJenkoKJIkawaMKimM-Jet al. 3-Substituted 1,5-Diaryl-1 H-1,2,4-Triazoles as Prospective PET Radioligands for Imaging Brain COX-1 in Monkey. Part 2: Selection and Evaluation of [(11)C]PS13 for Quantitative Imaging. ACS Chem Neurosci (2018) 9(11):2620–7. doi: 10.1021/acschemneuro.8b00103

  • 129

    ShresthaSKimMJEldridgeMLehmannMLFranklandMLiowJSet al. PET Measurement of Cyclooxygenase-2 Using a Novel Radioligand: Upregulation in Primate Neuroinflammation and First-in-Human Study. J Neuroinflamm (2020) 17(1):140. doi: 10.1186/s12974-020-01804-6

  • 130

    KumarJSDPrabhakaranJMolotkovASattirajuAKimJDoubrovinMet al. Radiosynthesis and Evaluation of [(18)F]FMTP, a COX-2 PET Ligand. Pharmacol Rep (2020) 72(5):1433–40. doi: 10.1007/s43440-020-00124-z

  • 131

    KumarJSDZanderigoFPrabhakaranJRubin-FalconeHParseyRVMannJJ. In Vivo Evaluation of [11C]TMI, a COX-2 Selective PET Tracer, in Baboons. Bioorg Med Chem Lett (2018) 28(23):3592–5. doi: 10.1016/j.bmcl.2018.10.049

  • 132

    YehSHHuangWSChiuCHChenCLChenHTChiDYet al. Automated Synthesis and Initial Evaluation of (4’-Amino-5’,8’-Difluoro-1’H-Spiro[Piperidine-4,2’-Quinazolin]-1-Yl)(4-[(18)F]fluorophenyl)methanone for PET/MR Imaging of Inducible Nitric Oxide Synthase. Mol Imaging (2021) 2021:9996125. doi: 10.1155/2021/9996125

  • 133

    HouCHsiehC-JLiSLeeHGrahamTJXuKet al. Development of a Positron Emission Tomography Radiotracer for Imaging Elevated Levels of Superoxide in Neuroinflammation. ACS Chem Neurosci (2018) 9(3):578–86. doi: 10.1021/acschemneuro.7b00385

  • 134

    EgamiHNakagawaSKatsuraYKanazawaMNishiyamaSSakaiTet al. (18)F-Labeled Dihydromethidine: Positron Emission Tomography Radiotracer for Imaging of Reactive Oxygen Species in Intact Brain. Org Biomol Chem (2020) 18(13):2387–91. doi: 10.1039/d0ob00126k

  • 135

    CarrollVNTruilletCShenBFlavellRRShaoXEvansMJet al. [11c]Ascorbic and [11C]Dehydroascorbic Acid, an Endogenous Redox Pair for Sensing Reactive Oxygen Species Using Positron Emission Tomography. Chem Commun (2016) 52(27):4888–90. doi: 10.1039/C6CC00895J

  • 136

    IkawaMOkazawaHTsujikawaTMatsunagaAYamamuraOMoriTet al. Increased Oxidative Stress is Related to Disease Severity in the ALS Motor Cortex: A PET Study. Neurology (2015) 84(20):2033–9. doi: 10.1212/wnl.0000000000001588

  • 137

    IkawaMOkazawaHKudoTKuriyamaMFujibayashiYYonedaM. Evaluation of Striatal Oxidative Stress in Patients With Parkinson’s Disease Using [62Cu]ATSM PET. Nucl Med Biol (2011) 38(7):945–51. doi: 10.1016/j.nucmedbio.2011.02.016

  • 138

    FujibayashiYTaniuchiHYonekuraYOhtaniHKonishiJYokoyamaA. Copper-62-ATSM: A New Hypoxia Imaging Agent With High Membrane Permeability and Low Redox Potential. J Nucl Med (1997) 38(7):1155–60.

  • 139

    TsujikawaTAsahiSOhMSatoYNaritaNMakinoAet al. Assessment of the Tumor Redox Status in Head and Neck Cancer by 62Cu-ATSM PET. PloS One (2016) 11(5):e0155635. doi: 10.1371/journal.pone.0155635

  • 140

    MeierSRSehlinDHultqvistGSyvänenS. Pinpointing Brain TREM2 Levels in Two Mouse Models of Alzheimer’s Disease. Mol Imaging Biol (2021) 23:s665–75. doi: 10.1007/s11307-021-01591-3

  • 141

    ChaneyAWilsonEJainPCropperHSwarovskiMLucotKet al. TREM1-PET Imaging of Pro-Inflammatory Myeloid Cells Distinguishes Active Disease From Remission in Multiple Sclerosis. J Nucl Med (2020) 61(supplement 1):199.

  • 142

    JohnsonEMurtySMayerATsaiCMehtaSIlovichOet al. TMIC-30. TREM1-TARGETED PET IMAGING OF TUMOR-ASSOCIATED MACROPHAGES IN AN ORTHOTOPIC GLIOBLASTOMA MOUSE MODEL. Neuro-Oncology (2017) 19(suppl_6):vi249–9. doi: 10.1093/neuonc/nox168.1019

  • 143

    LiuQJohnsonEMLamRKWangQBo YeHWilsonENet al. Peripheral TREM1 Responses to Brain and Intestinal Immunogens Amplify Stroke Severity. Nat Immunol (2019) 20(8):1023–34. doi: 10.1038/s41590-019-0421-2

  • 144

    ZhengQ-HFeiXDeGradoTRWangJ-QLee StoneKMartinezTDet al. Synthesis, Biodistribution and Micro-PET Imaging of a Potential Cancer Biomarker Carbon-11 Labeled MMP Inhibitor (2R)-2-[[4-(6-Fluorohex-1-Ynyl)Phenyl]Sulfonylamino]-3-Methylbutyric Acid [11C]Methyl Ester. Nucl Med Biol (2003) 30(7):753–60. doi: 10.1016/S0969-8051(03)00086-6

  • 145

    KastenBBJiangKColeDJaniAUdayakumarNGillespieGYet al. Targeting MMP-14 for Dual PET and Fluorescence Imaging of Glioma in Preclinical Models. Eur J Nucl Med Mol Imaging (2020) 47(6):1412–26. doi: 10.1007/s00259-019-04607-x

  • 146

    ButschVBörgelFGallaFSchwegmannKHermannSSchäfersMet al. Design, (Radio)Synthesis, and in Vitro and In Vivo Evaluation of Highly Selective and Potent Matrix Metalloproteinase 12 (MMP-12) Inhibitors as Radiotracers for Positron Emission Tomography. J Med Chem (2018) 61(9):4115–34. doi: 10.1021/acs.jmedchem.8b00200

  • 147

    BarcaCForayCHermannSDöringCSchäfersMJacobsAHet al. Characterization of the Inflammatory Post-Ischemic Tissue by Full Volumetric Analysis of a Multimodal Imaging Dataset. NeuroImage (2020) 222:117217. doi: 10.1016/j.neuroimage.2020.117217

  • 148

    ZinnhardtBVielTWachsmuthLVrachimisAWagnerSBreyholzH-Jet al. Multimodal Imaging Reveals Temporal and Spatial Microglia and Matrix Metalloproteinase Activity After Experimental Stroke. J Cereb Blood Flow Metab (2015) 35(11):1711–21. doi: 10.1038/jcbfm.2015.149

  • 149

    CailléFCacheuxFPeyronneauMAJegoBJaumainEPottierGet al. From Structure-Activity Relationships on Thiazole Derivatives to the In Vivo Evaluation of a New Radiotracer for Cannabinoid Subtype 2 PET Imaging. Mol Pharm (2017) 14(11):4064–78. doi: 10.1021/acs.molpharmaceut.7b00746

  • 150

    SavonenkoAVMelnikovaTWangYRavertHGaoYKoppelJet al. Cannabinoid CB2 Receptors in a Mouse Model of Aβ Amyloidosis: Immunohistochemical Analysis and Suitability as a PET Biomarker of Neuroinflammation. PloS One (2015) 10(6):e0129618. doi: 10.1371/journal.pone.0129618

  • 151

    NiRMüller HerdeAHaiderAKellerCLouloudisGVaasMet al. In Vivo Imaging of Cannabinoid Type 2 Receptors, Functional and Structural Alterations in Mouse Model of Cerebral Ischemia by PET and MRI. bioRxiv (2021) 2021:5.08.441033. doi: 10.1101/2021.05.08.441033

  • 152

    NiRMuLAmetameyS. Positron Emission Tomography of Type 2 Cannabinoid Receptors for Detecting Inflammation in the Central Nervous System. Acta Pharmacol Sin (2019) 40(3):351–7. doi: 10.1038/s41401-018-0035-5

  • 153

    MoldovanR-PTeodoroRGaoYDeuther-ConradWKranzMWangYet al. Development of a High-Affinity PET Radioligand for Imaging Cannabinoid Subtype 2 Receptor. J Med Chem (2016) 59(17):7840–55. doi: 10.1021/acs.jmedchem.6b00554

  • 154

    AhmadRPostnovABormansGVersijptJVandenbulckeMVan LaereK. Decreased In Vivo Availability of the Cannabinoid Type 2 Receptor in Alzheimer’s Disease. Eur J Nucl Med Mol Imaging (2016) 43(12):2219–27. doi: 10.1007/s00259-016-3457-7

  • 155

    YamagishiSIgaYNakamuraMTakizawaCFukumotoDKakiuchiTet al. Upregulation of Cannabinoid Receptor Type 2, But Not TSPO, in Senescence-Accelerated Neuroinflammation in Mice: A Positron Emission Tomography Study. J Neuroinflamm (2019) 16(1):208. doi: 10.1186/s12974-019-1604-3

  • 156

    VilaplanaERodriguez-VieitezEFerreiraDMontalVAlmkvistOWallAet al. Cortical Microstructural Correlates of Astrocytosis in Autosomal-Dominant Alzheimer Disease. Neurology (2020) 94(19):e2026–36. doi: 10.1212/wnl.0000000000009405

  • 157

    LemoineLGillbergPGBogdanovicNNennesmoISaint-AubertLViitanenMet al. Amyloid, Tau, and Astrocyte Pathology in Autosomal-Dominant Alzheimer’s Disease Variants: Aβpparc and PSEN1DE9. Mol Psychiatry (2020). doi: 10.1038/s41380-020-0817-2

  • 158

    MarutleAGillbergPGBergforsAYuWFNiRQNennesmoIet al. H-3-Deprenyl and H-3-PIB Autoradiography Show Different Laminar Distributions of Astroglia and Fibrillar Beta-Amyloid in Alzheimer Brain. J Neuroinflamm (2013) 10:861. doi: 10.1186/1742-2094-10-90

  • 159

    CarterSFChiotisKNordbergARodriguez-VieitezE. Longitudinal Association Between Astrocyte Function and Glucose Metabolism in Autosomal Dominant Alzheimer’s Disease. Eur J Nucl Med Mol Imaging (2019) 46(2):348–56. doi: 10.1007/s00259-018-4217-7

  • 160

    Rodriguez-VieitezECarterSFChiotisKSaint-AubertLLeuzyASchöllMet al. Comparison of Early-Phase 11c-Deuterium-L-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease. J Nucl Med (2016) 57(7):1071–7. doi: 10.2967/jnumed.115.168732

  • 161

    SchöllMCarterSFWestmanERodriguez-VieitezEAlmkvistOThordardottirSet al. Early Astrocytosis in Autosomal Dominant Alzheimer’s Disease Measured In Vivo by Multi-Tracer Positron Emission Tomography. Sci Rep (2015) 5:16404. doi: 10.1038/srep16404

  • 162

    Rodriguez-VieitezESaint-AubertLCarterSFAlmkvistOFaridKSchöllMet al. Diverging Longitudinal Changes in Astrocytosis and Amyloid PET in Autosomal Dominant Alzheimer’s Disease. Brain (2016) 139(Pt 3):922–36. doi: 10.1093/brain/awv404

  • 163

    Rodriguez-VieitezENiRQGulyasBTothMHaggkvistJHalldinCet al. Astrocytosis Precedes Amyloid Plaque Deposition in Alzheimer APPswe Transgenic Mouse Brain: A Correlative Positron Emission Tomography and In Vitro Imaging Study. Eur J Nucl Med Mol Imaging (2015) 42(7):1119–32. doi: 10.1007/s00259-015-3047-0

  • 164

    OlsenMAguilarXSehlinDFangXTAntoniGErlandssonAet al. Astroglial Responses to Amyloid-Beta Progression in a Mouse Model of Alzheimer’s Disease. Mol Imaging Biol (2018) 20(4):605–14. doi: 10.1007/s11307-017-1153-z

  • 165

    NagSFazioPLehmannLKettschauGHeinrichTThieleAet al. In Vivo and In Vitro Characterization of a Novel MAO-B Inhibitor Radioligand, 18f-Labeled Deuterated Fluorodeprenyl. J Nucl Med (2016) 57(2):315–20. doi: 10.2967/jnumed.115.161083

  • 166

    HaradaRHayakawaYEzuraMLerdsirisukPDuYIshikawaYet al. (18)F-SMBT-1: A Selective and Reversible PET Tracer for Monoamine Oxidase-B Imaging. J Nucl Med (2021) 62(2):253–8. doi: 10.2967/jnumed.120.244400

  • 167

    VillemagneVLLHaradaRDoreVFurumotoSMulliganRSKudoYet al. Evaluation of the Novel 18F-Labeled PET Tracer SMBT-1 for Imaging Astrogliosis in Healthy Elderly Controls and A+/T+/(N+) Alzheimer’s Disease Patients. Alzheimer’s Dementia (2020) 16(S4):e039858. doi: 10.1002/alz.039858

  • 168

    MoriguchiSWilsonAAMilerLRusjanPMVasdevNKishSJet al. Monoamine Oxidase B Total Distribution Volume in the Prefrontal Cortex of Major Depressive Disorder: An [11c]SL25.1188 Positron Emission Tomography Study. JAMA Psychiatry (2019) 76(6):634–41. doi: 10.1001/jamapsychiatry.2019.0044

  • 169

    RusjanPMWilsonAAMilerLFanIMizrahiRHouleSet al. Kinetic Modeling of the Monoamine Oxidase B Radioligand [¹¹C]SL25.1188 in Human Brain With High-Resolution Positron Emission Tomography. J Cereb Blood Flow Metab (2014) 34(5):883–9. doi: 10.1038/jcbfm.2014.34

  • 170

    NarayanaswamiVDrakeLRBrooksAFMeyerJHHouleSKilbournMRet al. Classics in Neuroimaging: Development of PET Tracers for Imaging Monoamine Oxidases. ACS Chem Neurosci (2019) 10(4):1867–71. doi: 10.1021/acschemneuro.9b00081

  • 171

    TakataKKatoHShimosegawaEOkunoTKodaTSugimotoTet al. 11c-Acetate PET Imaging in Patients With Multiple Sclerosis. PloS One (2014) 9(11):e111598. doi: 10.1371/journal.pone.0111598

  • 172

    DuongMTChenYJDootRKYoungAJLeeHCaiJet al. Astrocyte Activation Imaging With 11C-Acetate and Amyloid PET in Mild Cognitive Impairment Due to Alzheimer Pathology. Nucl Med Commun (2021). doi: 10.1097/mnm.0000000000001460

  • 173

    KumarAKoistinenNAMalarteMLNennesmoIIngelssonMGhettiBet al. Astroglial Tracer BU99008 Detects Multiple Binding Sites in Alzheimer’s Disease Brain. Mol Psychiatry (2021). doi: 10.1038/s41380-021-01101-5

  • 174

    WilsonHDervenoulasGPaganoGTyackeRJPolychronisSMyersJet al. Imidazoline 2 Binding Sites Reflecting Astroglia Pathology in Parkinson’s Disease: An In Vivo 11c-BU99008 PET Study. Brain (2019) 142(10):3116–28. doi: 10.1093/brain/awz260

  • 175

    TyackeRJMyersJFMVenkataramanAMickITurtonSPasschierJet al. Evaluation of (11)C-BU99008, a PET Ligand for the Imidazoline(2) Binding Site in Human Brain. J Nucl Med (2018) 59(10):1597–602. doi: 10.2967/jnumed.118.208009

  • 176

    CalsolaroVMatthewsPMDonatCKLivingstonNRFemminellaGDGuedesSSet al. Astrocyte Reactivity With Late-Onset Cognitive Impairment Assessed In Vivo Using 11C-BU99008 PET and its Relationship With Amyloid Load. Mol Psychiatry (2021). doi: 10.1038/s41380-021-01193-z

  • 177

    LivingstonNCalsolaroVHinzRNowellJRazaSGentlemanSet al. Relationship Between Astrocyte Reactivity, Using Novel 11 C-BU99008 PET, and Glucose Metabolism, Grey Matter Volume and Amyloid Load in Cognitively Impaired Individuals. medRxiv (2021). doi: 10.1101/2021.08.10.21261690

  • 178

    VenkataramanAVKeatNMyersJFTurtonSMickIGunnRNet al. First Evaluation of PET-Based Human Biodistribution and Radiation Dosimetry of (11)C-BU99008, a Tracer for Imaging the Imidazoline(2) Binding Site. EJNMMI Res (2018) 8(1):71. doi: 10.1186/s13550-018-0429-x

  • 179

    ParkerCANabulsiNHoldenDLinSFCassTLabareeDet al. Evaluation of 11C-BU99008, a PET Ligand for the Imidazoline2 Binding Sites in Rhesus Brain. J Nucl Med (2014) 55(5):838–44. doi: 10.2967/jnumed.113.131854

  • 180

    KawamuraKYamasakiTZhangYWakizakaHHatoriAXieLet al. Change in the Binding of [(11)C]BU99008 to Imidazoline I(2) Receptor Using Brain PET in Zucker Rats. Mol Imaging Biol (2019) 21(1):105–12. doi: 10.1007/s11307-018-1206-y

  • 181

    KawamuraKShimodaYYuiJZhangYYamasakiTWakizakaHet al. A Useful PET Probe [(11)C]BU99008 With Ultra-High Specific Radioactivity for Small Animal PET Imaging of I(2)-Imidazoline Receptors in the Hypothalamus. Nucl Med Biol (2017) 45:1–7. doi: 10.1016/j.nucmedbio.2016.10.005

  • 182

    KawamuraKShimodaYKumataKFujinagaMYuiJYamasakiTet al. In Vivo Evaluation of a New ¹⁸F-Labeled PET Ligand, [¹⁸F]FEBU, for the Imaging of I₂-Imidazoline Receptors. Nucl Med Biol (2015) 42(4):406–12. doi: 10.1016/j.nucmedbio.2014.12.014

  • 183

    KawamuraKMaedaJHatoriAOkauchiTNagaiYHiguchiMet al. In Vivo and In Vitro Imaging of I₂ Imidazoline Receptors in the Monkey Brain. Synapse (2011) 65(5):452–5. doi: 10.1002/syn.20897

  • 184

    KreimermanIReyesALPaolinoAPardoTPorcalWIbarraMet al. Biological Assessment of a 18F-Labeled Sulforhodamine 101 in a Mouse Model of Alzheimer’s Disease as a Potential Astrocytosis Marker. Front Neurosci (2019) 13:734. doi: 10.3389/fnins.2019.00734

  • 185

    GerwienHHermannSZhangXKorposESongJKopkaKet al. Imaging Matrix Metalloproteinase Activity in Multiple Sclerosis as a Specific Marker of Leukocyte Penetration of the Blood-Brain Barrier. Sci Trans Med (2016) 8(364):364ra152. doi: 10.1126/scitranslmed.aaf8020

  • 186

    NiRVaasMRenWKlohsJ. Noninvasive Detection of Acute Cerebral Hypoxia and Subsequent Matrix-Metalloproteinase Activity in a Mouse Model of Cerebral Ischemia Using Multispectral-Optoacoustic-Tomography. Neurophotonics (2018) 5(1):15005–10. doi: 10.1117/1.NPh.5.1.015005

  • 187

    GaoMWangMMeyerJAPetersJSZarrinmayehHTerritoPRet al. Synthesis and Preliminary Biological Evaluation of [(11)C]methyl (2-Amino-5-(Benzylthio)Thiazolo[4,5-D]Pyrimidin-7-Yl)-D-Leucinate for the Fractalkine Receptor (CX(3)CR1). Bioorg Med Chem Lett (2017) 27(12):2727–30. doi: 10.1016/j.bmcl.2017.04.052

  • 188

    CaryBPBrooksAFFawazMVDrakeLRDesmondTJShermanPet al. Synthesis and Evaluation of [(18)F]RAGER: A First Generation Small-Molecule PET Radioligand Targeting the Receptor for Advanced Glycation Endproducts. ACS Chem Neurosci (2016) 7(3):391–8. doi: 10.1021/acschemneuro.5b00319

  • 189

    ZhangYChenKSloanSABennettMLScholzeARKeeffeSet al. An RNA-Sequencing Transcriptome and Splicing Database of Glia, Neurons, and Vascular Cells of the Cerebral Cortex. J Neurosci (2014) 34(36):11929. doi: 10.1523/JNEUROSCI.1860-14.2014

  • 190

    ZhangYSloanSAClarkeLECanedaCPlazaCABlumenthalPDet al. Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences With Mouse. Neuron (2016) 89(1):37–53. doi: 10.1016/j.neuron.2015.11.013

  • 191

    RupprechtRPapadopoulosVRammesGBaghaiTCFanJAkulaNet al. Translocator Protein (18 kDa) (TSPO) as a Therapeutic Target for Neurological and Psychiatric Disorders. Nat Rev Drug Discov (2010) 9(12):971–88. doi: 10.1038/nrd3295

  • 192

    NotterTSchalbetterSMCliftonNEMatteiDRichettoJThomasKet al. Neuronal Activity Increases Translocator Protein (TSPO) Levels. Mol Psychiatry (2020). doi: 10.1038/s41380-020-0745-1

  • 193

    GuiYMarksJDDasSHymanBTSerrano-PozoA. Characterization of the 18 kDa Translocator Protein (TSPO) Expression in Post-Mortem Normal and Alzheimer’s Disease Brains. Brain Pathol (2020) 30(1):151–64. doi: 10.1111/bpa.12763

  • 194

    VivashLO’BrienTJ. Imaging Microglial Activation With TSPO PET: Lighting Up Neurologic Diseases? J Nucl Med (2016) 57(2):165–8. doi: 10.2967/jnumed.114.141713

  • 195

    RoivainenANågrenKHirvonenJOikonenVVirsuPTolvanenTet al. Whole-Body Distribution and Metabolism of [N-Methyl-11C](R)-1-(2-Chlorophenyl)-N-(1-Methylpropyl)-3-Isoquinolinecarboxamide in Humans; an Imaging Agent for In Vivo Assessment of Peripheral Benzodiazepine Receptor Activity With Positron Emission Tomography. Eur J Nucl Med Mol Imaging (2009) 36(4):671–82. doi: 10.1007/s00259-008-1000-1

  • 196

    PassamontiLTsvetanovKAJonesPSBevan-JonesWRArnoldRBorchertRJet al. Neuroinflammation and Functional Connectivity in Alzheimer’s Disease: Interactive Influences on Cognitive Performance. J Neurosci (2019) 39(36):7218. doi: 10.1523/JNEUROSCI.2574-18.2019

  • 197

    FanZCalsolaroVAtkinsonRAFemminellaGDWaldmanABuckleyCet al. Flutriciclamide (18f-GE180) PET: First-In-Human PET Study of Novel Third-Generation In Vivo Marker of Human Translocator Protein. J Nucl Med (2016) 57(11):1753–9. doi: 10.2967/jnumed.115.169078

  • 198

    FelskyDRoostaeiTNhoKRisacherSLBradshawEMPetyukVet al. Neuropathological Correlates and Genetic Architecture of Microglial Activation in Elderly Human Brain. Nat Commun (2019) 10(1):409. doi: 10.1038/s41467-018-08279-3

  • 199

    FemminellaGDDaniMWoodMFanZCalsolaroVAtkinsonRet al. Microglial Activation in Early Alzheimer Trajectory is Associated With Higher Gray Matter Volume. Neurology (2019) 92(12):e1331–43. doi: 10.1212/wnl.0000000000007133

  • 200

    TiwariAKJiBYuiJFujinagaMYamasakiTXieLet al. [18f]FEBMP: Positron Emission Tomography Imaging of TSPO in a Model of Neuroinflammation in Rats, and In Vitro Autoradiograms of the Human Brain. Theranostics (2015) 5(9):961–9. doi: 10.7150/thno.12027

  • 201

    JanssenBMachRH. Development of Brain PET Imaging Agents: Strategies for Imaging Neuroinflammation in Alzheimer’s Disease. Prog Mol Biol Transl Sci (2019) 165:371–99. doi: 10.1016/bs.pmbts.2019.04.005

  • 202

    JanssenBVugtsDJWindhorstADMachRH. PET Imaging of Microglial Activation-Beyond Targeting TSPO. Molecules (2018) 23(3). doi: 10.3390/molecules23030607

  • 203

    LinHLeeEHestirKLeoCHuangMBoschEet al. Discovery of a Cytokine and its Receptor by Functional Screening of the Extracellular Proteome. Science (2008) 320(5877):807–11. doi: 10.1126/science.1154370

  • 204

    HamiltonJA. Colony-Stimulating Factors in Inflammation and Autoimmunity. Nat Rev Immunol (2008) 8(7):533–44. doi: 10.1038/nri2356

  • 205

    MurphyMCCurranGLGlaserKJRossmanPJHustonJ3rdPodusloJFet al. Magnetic Resonance Elastography of the Brain in a Mouse Model of Alzheimer’s Disease: Initial Results. Magn Reson Imaging (2012) 30(4):535–9. doi: 10.1016/j.mri.2011.12.019

  • 206

    DuboisRNAbramsonSBCroffordLGuptaRASimonLSVan De PutteLBet al. Cyclooxygenase in Biology and Disease. FASEB J (1998) 12(12):1063–73. doi: 10.1096/fasebj.12.12.1063

  • 207

    ChoiS-HAidSBosettiF. The Distinct Roles of Cyclooxygenase-1 and -2 in Neuroinflammation: Implications for Translational Research. Trends Pharmacol Sci (2009) 30(4):174–81. doi: 10.1016/j.tips.2009.01.002

  • 208

    UmeozuluSYoungNTaddeiCSimeonFPikeV. Chemical Studies Aimed at Developing Improved PET Radioligands for Imaging Brain Cyclooxygenase-2. J Nucl Med (2021) 62(supplement 1):1448.

  • 209

    LitchfieldMWuestMGlubrechtDWuestF. Radiosynthesis and Biological Evaluation of [(18)F]Triacoxib: A New Radiotracer for PET Imaging of COX-2. Mol Pharm (2020) 17(1):251–61. doi: 10.1021/acs.molpharmaceut.9b00986

  • 210

    JiBKumataKOnoeHKanekoHZhangMRSekiCet al. Assessment of Radioligands for PET Imaging of Cyclooxygenase-2 in an Ischemic Neuronal Injury Model. Brain Res (2013) 1533:152–62. doi: 10.1016/j.brainres.2013.08.026

  • 211

    ShukuriMTakashima-HiranoMTokudaKTakashimaTMatsumuraKInoueOet al. In Vivo Expression of Cyclooxygenase-1 in Activated Microglia and Macrophages During Neuroinflammation Visualized by PET With 11C-Ketoprofen Methyl Ester. J Nucl Med (2011) 52(7):1094. doi: 10.2967/jnumed.110.084046

  • 212

    EvensNBosierBLaveyBJKozlowskiJAVermaelenPBaudemprezLet al. Labelling and Biological Evaluation of [(11)C]methoxy-Sch225336: A Radioligand for the Cannabinoid-Type 2 Receptor. Nucl Med Biol (2008) 35(7):793–800. doi: 10.1016/j.nucmedbio.2008.07.004

  • 213

    Di VirgilioFDal BenDSartiACGiulianiALFalzoniS. The P2X7 Receptor in Infection and Inflammation. Immunity (2017) 47(1):15–31. doi: 10.1016/j.immuni.2017.06.020

  • 214

    CserépCPósfaiBLénártNFeketeRLászlóZILeleZet al. Microglia Monitor and Protect Neuronal Function Through Specialized Somatic Purinergic Junctions. Science (2020) 367(6477):528–37. doi: 10.1126/science.aax6752

  • 215

    ZrzavyTHametnerSWimmerIButovskyOWeinerHLLassmannH. Loss of ’Homeostatic’ Microglia and Patterns of Their Activation in Active Multiple Sclerosis. Brain J Neurol (2017) 140(7):1900–13. doi: 10.1093/brain/awx113

  • 216

    BadimonAStrasburgerHJAyataPChenXNairAIkegamiAet al. Negative Feedback Control of Neuronal Activity by Microglia. Nature (2020) 586(7829):417–23. doi: 10.1038/s41586-020-2777-8

  • 217

    MildnerAHuangHRadkeJStenzelWPrillerJ. P2Y(12) Receptor Is Expressed on Human Microglia Under Physiological Conditions Throughout Development and is Sensitive to Neuroinflammatory Diseases. Glia (2017) 65(2):375–87. doi: 10.1002/glia.23097

  • 218

    FuZLinQHuBZhangYChenWZhuJet al. P2X7 PET Radioligand (18)F-PTTP for Differentiation of Lung Tumor From Inflammation. J Nucl Med (2019) 60(7):930–6. doi: 10.2967/jnumed.118.222547

  • 219

    DrakeLRBrooksAFMufarrehAJPhamJMKoeppeRAShaoXet al. Deuterium Kinetic Isotope Effect Studies of a Potential In Vivo Metabolic Trapping Agent for Monoamine Oxidase B. ACS Chem Neurosci (2018) 9(12):3024–7. doi: 10.1021/acschemneuro.8b00219

  • 220

    TessonFLimon-BoulezIUrbanPPuypeMVandekerckhoveJCoupryIet al. Localization of I2-Imidazoline Binding Sites on Monoamine Oxidases. J Biol Chem (1995) 270(17):9856–61. doi: 10.1074/jbc.270.17.9856

  • 221

    ParkerCANabulsiNHoldenDLinS-FCassTLabareeDet al. Tyacke: Evaluation of 11C-BU99008, a PET Ligand for the Imidazoline2 Binding Sites in Rhesus Brain. J Nucl Med (2014) 55(5):838. doi: 10.2967/jnumed.113.131854

  • 222

    HanssonO. Biomarkers for Neurodegenerative Diseases. Nat Med (2021) 27(6):954–63. doi: 10.1038/s41591-021-01382-x

  • 223

    NiRGillbergPGBogdanovicNViitanenMMyllykangasLNennesmoIet al. Amyloid Tracers Binding Sites in Autosomal Dominant and Sporadic Alzheimer’s Disease. Alzheimers Dement (2017) 13(4):419–30. doi: 10.1016/j.jalz.2016.08.006

  • 224

    PeraniDIaccarinoLJacobsAH. Application of Advanced Brain Positron Emission Tomography-Based Molecular Imaging for a Biological Framework in Neurodegenerative Proteinopathies. Alzheimers Dement (Amst) (2019) 11:327–32. doi: 10.1016/j.dadm.2019.02.004

  • 225

    PeraniDIaccarinoLLammertsmaAAWindhorstADEdisonPBoellaardRet al. A New Perspective for Advanced Positron Emission Tomography-Based Molecular Imaging in Neurodegenerative Proteinopathies. Alzheimers Dement (2019) 15(8):1081–103. doi: 10.1016/j.jalz.2019.02.004

  • 226

    NutmaECeyzériatKAmorSTsartsalisSMilletPOwenDRet al. Cellular Sources of TSPO Expression in Healthy and Diseased Brain. Eur J Nucl Med Mol Imaging (2021). doi: 10.1007/s00259-020-05166-2

  • 227

    NutmaEStephensonJAGorterRPde BruinJBoucherieDMDonatCKet al. A Quantitative Neuropathological Assessment of Translocator Protein Expression in Multiple Sclerosis. Brain J Neurol (2019) 142(11):3440–55. doi: 10.1093/brain/awz287

  • 228

    TournierBBTsartsalisSCeyzériatKMedinaZFraserBHGrégoireMCet al. Fluorescence-Activated Cell Sorting to Reveal the Cell Origin of Radioligand Binding. J Cereb Blood Flow Metab (2020) 40(6):1242–55. doi: 10.1177/0271678x19860408

  • 229

    PannellMEconomopoulosVWilsonTCKersemansVIseneggerPGLarkinJRet al. Imaging of Translocator Protein Upregulation Is Selective for Pro-Inflammatory Polarized Astrocytes and Microglia. Glia (2020) 68(2):280–97. doi: 10.1002/glia.23716

  • 230

    CagninABrooksDJKennedyAMGunnRNMyersRTurkheimerFEet al. In-Vivo Measurement of Activated Microglia in Dementia. Lancet (2001) 358(9280):461–7. doi: 10.1016/s0140-6736(01)05625-2

  • 231

    YokokuraMMoriNYagiSYoshikawaEKikuchiMYoshiharaYet al. In Vivo Changes in Microglial Activation and Amyloid Deposits in Brain Regions With Hypometabolism in Alzheimer’s Disease. Eur J Nucl Med Mol Imaging (2011) 38(2):343–51. doi: 10.1007/s00259-010-1612-0

  • 232

    WileyCALoprestiBJVennetiSPriceJKlunkWEDeKoskySTet al. Carbon 11-Labeled Pittsburgh Compound B and Carbon 11-Labeled (R)-PK11195 Positron Emission Tomographic Imaging in Alzheimer Disease. Arch Neurol (2009) 66(1):60–7. doi: 10.1001/archneurol.2008.511

  • 233

    GroomGNJunckLFosterNLFreyKAKuhlDE. PET of Peripheral Benzodiazepine Binding Sites in the Microgliosis of Alzheimer’s Disease. J Nucl Med (1995) 36(12):2207–10.

  • 234

    AlbrechtDSSagareAPachicanoMSweeneyMDTogaAZlokovicBet al. Early Neuroinflammation is Associated With Lower Amyloid and Tau Levels in Cognitively Normal Older Adults. Brain Behav Immun (2021) 94:299–307. doi: 10.1016/j.bbi.2021.01.010

  • 235

    JiBChenC-JBandoKAshinoHShiraishiHSanoHet al. Distinct Binding of Amyloid Imaging Ligands to Unique Amyloid-β Deposited in the Presubiculum of Alzheimer’s Disease. J Neurochem (2015) 135(5):859–66. doi: 10.1111/jnc.13293

  • 236

    KongYHuangLLiWLiuXZhouYLiuCet al. The Synaptic Vesicle Protein 2a Interacts With Key Pathogenic Factors in Alzheimer’s Disease: Implications for Treatment. Front Cell Dev Biol (2021) 9:1555. doi: 10.3389/fcell.2021.609908

Summary

Keywords

Alzheimer’s disease, neuroinflammation, tau, microglia, astrocyte, amyloid (A) 42, positron emission tomography (PET), TSPO (18 kDa translocator protein)

Citation

Zhou R, Ji B, Kong Y, Qin L, Ren W, Guan Y and Ni R (2021) PET Imaging of Neuroinflammation in Alzheimer’s Disease. Front. Immunol. 12:739130. doi: 10.3389/fimmu.2021.739130

Received

10 July 2021

Accepted

27 August 2021

Published

16 September 2021

Volume

12 - 2021

Edited by

Maya Koronyo-Hamaoui, Cedars Sinai Medical Center, United States

Reviewed by

Neil Vasdev, Centre for Addiction and Mental Health (CAMH), Canada; Nazanin Mirzaei, Life Molecular Imaging GmbH, Germany

Updates

Copyright

© 2021 Zhou, Ji, Kong, Qin, Ren, Guan and Ni.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Yihui Guan, ; Ruiqing Ni,

†These authors have contributed equally to this work

This article was submitted to Multiple Sclerosis and Neuroimmunology, a section of the journal Frontiers in Immunology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Share on WeChat

Scan with WeChat to share this article

Article metrics